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CHAPTER I 
 
INTRODUCTION  
 
Overview 
Diabetes is a growing pandemic both in the United States and around the world. 
In the last decade the number of cases of diabetes has risen steadily with the current 
approximation being 26 million people affected in the United States alone.
1
 Much of this 
rise is due to the increase in prevalence of type 2 diabetes. While type 1 and type 2 
diabetes have different etiologies, the symptoms and complications of each are similar. 
Diabetes starts with dysfunction in the pancreas, but it has many systemic effects that 
contribute to serious health problems. It is the currently leading cause of kidney failure, 
new cases of blindness, and non-traumatic lower limb amputations. Other major 
complications of diabetes include heart disease, stroke, hypertension, periodontal disease 
and nerve damage. The main focus of this work is to study the molecular changes 
associated with kidney damage due to diabetes.  
Approximately one-third of all diabetic patients will develop diabetic nephropathy 
(DN) and many will go on to develop end stage renal disease (ESRD) requiring continual 
renal dialysis or kidney transplant.
2
 Much still remains unknown about the pathogenesis 
of this disease and insight for prevention and better treatment options of DN can lower 
the incidence of ESRD. This project will investigate the molecular changes that take 
place in glomeruli and tubules to explore the pathogenic mechanisms of this disease by 
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use of mass spectrometry. Specifically, matrix assisted laser desorption/ionization 
(MALDI) imaging mass spectrometry (IMS) will be used to determine the spatial 
distribution of different molecules within the kidney. The goal of this research project is 
to develop MALDI MS methods for direct tissue analysis of individual glomeruli and 
tubules within the kidney cortex by imaging mass spectrometry and histology directed 
profiling techniques. These methods will then be applied to study an experimental model 
of diabetic nephropathy. Determining biomolecules that undergo change in disease 
conditions and evaluating response to treatment may lead to new molecular markers of 
disease, provide insight into disease pathogenesis, and characterize treatment response. 
Diabetic Nephropathy 
Diabetic nephropathy (DN) is a major health complication for diabetic patients 
and is the leading cause of end stage renal disease (ESRD).
2
 Diabetic patients with ESRD 
are more difficult to manage and experience an increased death rate.
1 
The incidence of 
diabetes has increased rapidly over the past decade and thus the number of cases of DN is 
rising as well. DN develops in 30 to 40% of type 1 and type 2 diabetic patients. Poor 
treatment and/or genetic disposition in diabetic individuals lead to increased severity of 
complications. DN is a progressive disease and is classified into stages: microalbuminuria 
and macroalbuminuria.
3
 Pathologic and morphologic changes that are characteristic of 
late stage diabetic nephropathy include albuminuria, increased glomerular basement 
membrane thickness, mesangial expansion, focal segmental and early nodular 
glomerulosclerosis, and markedly decreased glomerular filtration rate. Although there is 
not a clear understanding of the molecular basis of the pathology of DN, it is known that 
early detection and maintenance are critical in delaying the progress of the disease.  
3 
 
Molecular Mechanisms of Disease 
Diabetic nephropathy is a complex disease that involves many factors. It is 
characterized by the accumulation of extracellular matrix (ECM) in the glomerular and 
tubular basement membranes and expansion of the glomerular mesangial matrix 
decreasing the kidney’s function to filter the body’s blood. While DN develops in some 
patients with diabetes, it does not develop in others, even with persistent hyperglycemia. 
This observation has led to the idea that a subset of patients have an increased 
susceptibility to DN
3
 likely based on both genetic and environmental factors. While much 
remains unknown about the pathogenesis of DN, sustained hyperglycemia and 
hypertension are important in both initiation and progression of this kidney disease. 
These metabolic and hemodynamic factors are the main focus of both research and 
treatment efforts.
3-7
 There are several pathways that have been found to contribute to 
pathogenic mechanisms in diabetic kidney disease. These pathways include increased 
generation of advanced glycation end products (AGEs), activation of protein kinase C, 
and increased flux through the hexosamine and polyol pathways.
5, 8-10
 There is cross-talk 
among these pathways but all have been shown to contribute to ECM accumulation and 
renal injury. Protein kinase C, hexosamines, and AGEs have been shown to activate 
transforming growth factor-β (TGF-β) signaling. TGF-β is a major molecule responsible 
for increased synthesis of collagen type I and IV, fibronectin, laminin and other ECM 
proteins.
11
 
12
 AGEs are a group of molecules formed by the non-enzymatic reaction of a 
sugar with free amino groups on proteins, lipids, and nucleic acids and can form both 
intracellularly and extracellularly. AGEs are produced in small amounts under normal 
conditions of aging; however their formation increases under high glucose conditions. In 
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the extracellular environment, AGEs can accumulate in long-lived ECM proteins which 
have been shown to alter the ECM composition and effect glomerular cell-matrix 
interactions and thus may cause cellular dysfunction.
13-15
 All of these pathways have been 
found to have high glucose and reactive oxygen species (ROS) as common denominators. 
This has led to the proposition of a unifying mechanism by Brownlee et al whereby 
hyperglycemia induces overproduction of mitochondrial ROS
8, 16
 leading to pathogenesis 
of diabetic complications.  
Diagnosis, Prevention, and Current Treatment Options 
The most accurate diagnosis of DN in the clinic is kidney biopsy revealing 
arteriolar hyalinosis, increased GBM thickness, mesangial expansion, mesangiolysis, 
focal segmental and early nodular glomerulosclerosis.
17
 However, due the invasive nature 
of biopsy, DN is most often diagnosed with positive proteinuria.
3
 Currently there is no 
way to reverse the damage in kidneys of DN patients, and as damage accumulates over 
time these patients will progress to ESRD. Prevention is the first line of defense. Tightly 
controlled blood glucose has been found to be the best prevention of DN. 
Current treatment options are limited and include tighter control of glucose levels 
for better maintenance along with drugs to control blood pressure. These therapies will 
only slow, and not prevent, progression to ESRD. Once kidney damage has begun, 
maintenance becomes very important. Pharmaceuticals that target the rennin-angiotensin 
pathway and control renal hemodynamics are currently the only approved drugs for DN
18
 
as it has been found that in conjunction with blood glucose control, blood pressure 
control also becomes paramount in maintaining kidney function. Angiotensin-converting 
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enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are the most 
commonly prescribed drugs.  
A new drug, pyridoxamine (PM) (Figure 1.1), currently in phase II clinical trials, 
has a different mechanism of action than the currently approved DN drugs by targeting 
molecules directly involved in the disease mechanism. Prolonged hyperglycemia disrupts 
many metabolic pathways by production of reactive oxygen species (ROS), reactive 
carbonyl intermediates, and AGEs. Mechanisms whereby PM protects renal function 
include inhibition of toxic oxidative and glycoxidative reactions via scavenging of 
reactive oxygen and carbonyl species and via sequestration of catalytically active 
transition metal ions.
19-23
 A number of preclinical and phase II trials have shown that 
pyridoxamine preserves kidney function,
24-28
 particularly at the early stages of the 
disease.
29
  
 
 
 
Figure 1.1. Structure of pyridoxamine (PM).  
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Structure and Function of the Kidney 
The kidney’s primary function is to remove waste from the bloodstream and to 
maintain proper electrolyte and fluid balance for the body. Filtration is achieved through 
the nephron which is the main structural and functional unit of the kidney. Humans have 
about one million of these functional nephron units per kidney. A single nephron is 
composed of a glomerulus enclosed by the Bowman’s capsule, a proximal tubule, loop of 
Henle, distal tubule and a collecting duct (Figure 1.2). Filtration begins at the glomerulus 
which is a small spherical structure consisting of mesangial cells, capillary endothelial 
cells, podocytes, and extracellular matrix (see Figure 1.3). The glomerular filtration 
membrane functions as both a size and charge barrier
30
 where water, small molecules, 
and small proteins can pass through while large proteins and red blood cells do not pass 
through the capillary walls. Unfiltered blood enters into the glomerulus through the 
afferent arteriole and travels through the densely packed capillaries. The water and 
soluble waste that pass through the fenestrated endothelial cells of the capillaries leaves 
the glomerulus and continues to the proximal tubule to be excreted as urine. Filtered 
blood exits the glomerulus through the efferent arteriole to return to the body. About 150 
liters of blood are filtered through the glomeruli per day. Most of this fluid is reabsorbed 
along the tubule concentrating to produce about 1 liter of urine per day. In humans the 
glomerulus is about 150 μm in diameter and in mice it is approximately 80 μm in 
diameter. Diseases of the kidney, such as diabetic nephropathy, disrupt the filtering 
process and reduce the function of the kidney. 
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Figure 1.2. Kidney structure.  The nephron is the basic structural and functional unit of 
the kidney. Each nephron of the kidney contains a renal corpuscle and tubule. The 
corpuscle consists of the glomerulus and the Bowman’s capsule and is shown on the left. 
The tubular portion of the nephron consists of the proximal convoluted tubule, the loop of 
Henle, and the distal convoluted tubule. As the filtrate flows through the tubule of the 
nephron, it becomes increasingly concentrated into urine. Waste products are transferred 
from the blood into the filtrate, while nutrients are absorbed from the filtrate into the 
blood. 
 
* Reproduced with permission of Encyclopædia Britannica® Online from: renal 
corpuscle, in Encyclopædia Britannica Online [Online] 2014. 
http://www.britannica.com/EBchecked/media/107139/Each-nephron-of-the-kidney-
contains-blood-vessels-and-a. 
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Figure 1.3. Schematic of a mature glomerulus in cross section. Fewer capillary loops are 
shown than normal for clarity, and the size of cells are exaggerated in proportion to the 
overall size of the glomerulus. The four major cell types of the glomerulus are the 
Bowman's capsule (BC) or parietal epithelium (grey), podocytes (P, blue) or visceral 
epithelium, mesangial cells (M, orange) and endothelial cells (E, red). The mature 
glomerulus is encompassed by the Bowman's capsule. The glomerulus comprises a self-
contained network of capillary loops (C, red), with mesangial cells forming a nexus at the 
base of the capillary network. The glomerular basement membrane (GBM, green) divides 
the glomerulus into two compartments, an inner one containing the capillaries and the 
mesangial cells, and an outer one containing podocytes and the space into which the 
filtrate passes. The glomerulus remains connected to the remainder of the nephron 
through an opening in the Bowman's capsule that connects the glomerulus to the 
proximal tubule, shown on the right. The arrows in the capillaries indicate the flow of 
blood in and out of the glomerulus. Also omitted for clarity is the branching of the single 
capillary loop into the multiple loops within each glomerulus. 
 
* Reproduced with permission of COMPANY OF BIOLOGISTS from: Quaggin S E, and 
Kreidberg J A Development 2008; 135:609-620. 
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Current Research in DN 
Current DN research involves studies using both humans and animal models of 
the disease. Research with human subjects is usually in the form of clinical trials
31-33
 or 
cohort studies.
34
 These often look at end-points in accessible material such as blood or 
urine.  Kidney biopsy is not standard procedure for diagnosis due to its invasiveness. As 
such, research directly with human renal tissue is less common but include proteomic 
studies of human glomeruli
35
 and  histopathology studies from biopsies that have 
established structural and functional relationships between biopsies and clinical 
manifestations.
36
  
Animal models are important in clinical research. These give investigators more 
control over the experimental system and allow for more in-depth investigation directly at 
the site of disease with access to organs. Animal models allow for a variety of 
experimental designs including controlled studies of experimental therapies, 
investigations into disease progression, specific molecular pathways or proteins and full 
scale proteomics studies. Specific to DN, a number of rodent models have been 
employed.
37
 In this present study the double mutant eNOS
-/-
 db/db mouse was utilized. 
The db/db mouse is a common strain used as a Type II diabetes model and has a mutation 
in the leptin receptor leading to obesity and hyperglycemia. Mice with a mutation 
targeting endothelial nitric oxide synthase (eNOS
-/-
) have a deficiency in eNOS which 
leads to hypertension. Crossing these two mouse strains leads to double mutant mice that 
exhibit hyperglycemia and hypertension and also develop significant albuminuria, 
basement membrane thickness, mesangial expansion and decreased glomerular filtration 
10 
 
rate. This is the most robust DN model available and closely mimics the human 
disease.
38, 39
 
Along with this mouse model, a new technology to DN research being utilized in 
this work is imaging mass spectrometry (IMS). This technology has specific advantages 
in that it provides native molecular distributions while maintaining the spatial integrity of 
the tissue, can be interfaced directly with histology, is inherently multiplexed, and 
suitable for investigations of a wide variety of biomolecules including metabolites, lipids, 
peptides, and proteins. Additionally, IMS is a good discovery tool as no target specific 
reagents are required. This is an intriguing application of IMS as much remains unknown 
about the molecular pathways involved in the pathogenesis of DN.  
MALDI Mass Spectrometry  
Mass spectrometry (MS) allows for simultaneous detection of multiple analytes 
without the need for labeling or a priori knowledge of the system under investigation. A 
mass spectrum is a graph of ion intensity plotted as a function of the mass-to-charge (m/z) 
ratio of ions detected in the gas phase. Two common sources of these gas phase ions are 
matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI). 
MALDI was developed in the 1980’s through the pioneering work in the lab of Tanaka40 
and the lab of Karas and Hillenkamp.
41, 42
 Around this same time John Fenn developed 
ESI.
43
 The development of these two soft ionization techniques revolutionized the 
analysis of large biomolecules. Fenn and Tanaka earned a share of the 2002 Nobel Prize 
in chemistry for their respective developments of ESI and MALDI. As MALDI MS is the 
focus of this present work, a brief description of the process and instrumentation used 
will be described below. 
11 
 
In a typical MALDI experiment, a sample is mixed and co-crystallized with a 
suitable matrix (Figure 1.4). The matrix is usually a small organic compound that 
functions to absorb the energy of the laser light and assist in desorption and ionization of 
a sample. As most commercial MALDI instruments are equipped with UV lasers of 
nitrogen (337 nm), or solid state frequency tripled Nd:YAG (355 nm) or Nd:YLF (349 
nm), matrix compounds that strongly absorb the wavelength of the UV laser are generally 
required. Common matrices that have been used successfully for a variety of 
biomolecules include 2,5-dihydroxybenzoic acid (DHB), sinapinic acid (SA) and α-
cyano-4-hydroxycinnamic acid (CHCA). The MALDI process generally produces singly 
charged ions and usually does not induce fragmentation allowing for easy spectral 
interpretation.   
TOF Analyzers 
MALDI sources are commonly interfaced with time of flight (TOF) mass 
analyzers. TOF analyzers determine the mass-to-charge of an ion based on the time it 
takes an ion to traverse a field free region following acceleration and subsequently hit a 
detector. These are some of the simplest mass analyzers containing the basic components 
of an accelerating electrode, a field free drift region, and a detector (Figure 1.5). The 
detector in TOF instruments is often a multi-channel plate detector. The basis of TOF 
mass analyzers is that when ions are given the same kinetic energy through acceleration, 
ions with different masses will have different velocities and therefore will be separated in 
time. The pulsed nature of a laser provides an inherent ‘start’ time that makes TOF 
analyzers a perfect match with a MALDI source. When ions are created in the source 
region after the laser pulse, they are accelerated and enter a field-free drift region where  
12 
 
 
 
 
 
 
 
Figure 1.4. Schematic of MALDI process. A laser pulse irradiates a sample-matrix 
surface. The matrix absorbs the laser energy to assist in desorption and ionization of 
sample analytes. 
13 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. TOF schematic. A simplified linear mode MALDI TOF schematic where ions 
generated from the sample by the laser are accelerated and traverse a field-free drift 
region of length d and hit a detector. The time of flight is measured and converted to a 
mass-to-charge ratio (m/z).   
14 
 
they are separated based on their velocity. The kinetic energy of an ion is described by 
the following equation:  
      
   
 
 
where z is the charge of the ion, V is the ion acceleration voltage, m is the mass of the ion, 
and v is the velocity of the ion. All ions are given the same kinetic energy based on the 
voltage applied in the source; therefore, the time it takes for an ion to reach the detector is 
given by the equation: 
   √
 
   
 
where t is time and d is the distance the ion travels (i.e., the length of the flight tube). 
Based on the equation above, an ion’s mass is proportional to the time that it travels; 
therefore ions with higher m/z will reach the detector at a later time than smaller m/z ions.  
A major limitation of the basic TOF analyzer is mass resolution. Two key 
instrumental advancements, the reflectron configuration and delayed extraction,
44, 45
 have 
greatly improved the practical mass resolution achieved with MALDI TOF mass 
spectrometers. Both the reflectron analyzer and delayed extraction can correct for the 
broad initial velocity distribution of ions in the plume after a laser pulse. Reflectron 
instruments use an electrostatic field to reflect the ions toward the detector. Ions with 
higher initial velocities will penetrate deeper into the field and therefore travel a longer 
distance than an ion of the same mass-to-charge but a lower initial velocity. This focuses 
the ions of the same mass-to-charge and allows them to reach the detector at the same 
time. Reflectron instruments also have a longer flight path further improving resolution. 
Delayed extraction is used on both linear and reflectron TOF analyzers to improve 
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resolution. When instruments are operated under constant electric fields, ions of the same 
mass but different initial velocities will arrive at the detector at different times. The 
spread of initial velocities can be corrected by pulsing the acceleration field after a given 
delay, typically one to several hundred nanoseconds. In this manner, ions with higher 
initial velocities towards the extraction region will be accelerated slower to reach the 
potential and ions with lower initial velocities will be accelerated faster to reach this same 
potential. With the correct parameters for delay time and pulsed field strength, ions with 
different initial velocities but the same mass should arrive at the detector at the same 
time.   
MALDI TOF instruments have a very high duty cycle with some instruments 
equipped with 5 kHz lasers. This high duty cycle along with the theoretically unlimited 
mass range of TOF analyzers make these instruments well-matched for bimolecular 
imaging as they are fast and suitable for detection of a wide range of biomolecules from 
small molecules to large proteins.  
FTICR Mass Analyzers 
Fourier transform ion cyclotron resonance (FTICR) mass spectrometers are another type 
of mass analyzer that can be interfaced with MALDI. Reviews and fundamentals are 
covered extensively elsewhere
46-48
 and only the basics will be covered here. FTICR mass 
spectrometers consist of an ICR cell located in the center of a super-conducting magnet 
which provides a uniform magnetic field. The basis for FTICR mass analyzers is that ions 
will undergo cyclotron motion in a magnetic field. This cyclotron motion causes ions to 
travel in a circular orbit with a frequency that is dependent on its mass. A typical ICR cell 
consists of three sets of plates: two trapping plates, two excitation plates, and two 
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detection plates (Figure 1.6). The trapping plates are perpendicular to the magnetic field 
and after ions are transferred into the ICR cell a small voltage is applied to each end 
creating a potential well that traps the ions in the cell. Ions typically have very small 
initial orbits inside the cell. For detection, a radio frequency (RF) potential is applied to 
the excitation plates. When the RF frequency corresponds to the cyclotron frequency of 
an ion it will spiral outward with increasing orbit radius (see Figure 1.6). The RF is then 
turned off and the ion undergoes cyclotron motion with a radius large enough for an 
image current to be produced at the detection plates. If applied continuously, the ions will 
spiral outward until they hit one of the plates and are neutralized. 
The force on an ion as it enters a magnetic field is described by the following 
equation: 
       
where B is the strength of the magnetic field and z and v are the charge and velocity of 
the ion, respectively. This force is call the Lorentz force and causes the ion to have 
circular motion that is perpendicular to the magnetic field. The centripetal force must 
equal the magnetic force therefore the following equation is true: 
      
   
 
 
Since the distance an ion travels in one rotation is 2πr, the above equation can be 
rearranged to describe the frequency as:  
  
  
   
 
As seen in the above equation, the ion’s cyclotron frequency is only dependent on the 
strength of the magnetic field and its mass-to-charge ratio and is independent of its 
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Figure 1.6. FTICR schematic. Incoherent ion cyclotron orbital motion (top left) is 
converted to coherent (and, therefore, detectable) motion (top right) by the application of 
a rotating electric field, which rotates in the same sense and at the ICR frequency of the 
ions of a given m/z value. The electronic circuitry is shown in the bottom diagram. 
 
* Reproduced with permission from: Marshall, A. G.; Hendrickson, C. L.; 
Jackson, G. S., Fourier transform ion cyclotron resonance mass spectrometry: A primer. 
Mass Spectrometry Reviews 1998, 17 (1), 1-35. 
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velocity and kinetic energy. Therefore, constant, homogenous, and unidirectional 
magnetic fields allow for high mass accuracy and high mass resolving power.   
FTICR instruments are the highest performance mass spectrometers available. 
They achieve both high resolving power (routinely >100,000) and high mass accuracy 
(sub ppm) lending great value in the analysis of biomolecules. Unlike MALDI TOF 
instruments where every laser shot results in a detection event, MALDI FTICR 
instruments can accumulate ions from multiple laser shots before the detection event 
leading to increased sensitivity for detection of low abundant molecules. However, the 
detection event is much longer in an FTICR compared to a TOF (typically seconds vs. 
microseconds) leading to longer analysis times, particularly in an imaging experiment.   
Imaging Mass Spectrometry 
Combining mass spectrometry with an imaging approach adds yet another layer to 
the dataset providing the spatial distribution of each detected ion within an analysis area. 
Current imaging MS technologies include secondary ion mass spectrometry (SIMS), laser 
desorption ionization (LDI), desorption electrospray ionization (DESI), and MALDI. 
SIMS is one of the earliest platforms used for imaging and provides the highest spatial 
resolution by using a focused primary ion beam incident on the surface of a sample. 
Resolution of 50 nm can be achieved but this technique has a limited mass range of ~ m/z 
1000, often producing elemental ions or fragments of surface molecules.
49, 50
 
Applications with LDI have reported spatial resolutions of <1 µm but again, has been 
limited in mass range due to fragmentation of molecules.
51-53
 MALDI IMS is probably 
the most widely used MS imaging platform due to the extended mass range and low 
fragmentation of ionized molecules. Conventional MALDI MS can detect masses that 
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span several orders of magnitude, extending beyond m/z 300,000. However, the spatial 
resolution is lower than that of SIMS and LDI imaging where typical MALDI laser spot 
sizes are 30-200 μm, although spot sizes of 1 μm have been reported.54  
MALDI IMS is the focus of this work and has been described extensively 
elsewhere,
55-58
 but advancements and applications will be briefly outlined here. Since 
MALDI IMS was first described in 1997 where it was applied to map peptides and 
proteins in a thin tissue section,
59
 this technology has been used in many other studies to 
map a wide range of biomolecules including proteins, peptides,
60
 lipids,
61, 62
 
pharmaceuticals and metabolites.
63
 The diversity of molecules suitable for detection with 
this technology has lent itself to use in a broad range of applications, most notably, in the 
arenas of biology and medicine. With respect to these areas, MALDI IMS has been 
instrumental in classifying tumor types in studies including lung, melanoma, and breast 
cancers,
64-66
 determining proteomic patterns of specific cell types in autoimmune liver 
diseases,
67
 determining tissue drug distributions,
63, 68
 and identifying candidate markers 
of disease.
69, 70
  
The value of MALDI IMS has increased as the technology has developed. 
Progress in the areas of spatial resolution,
71-74
 sensitivity,
75, 76
 speed,
77
 and sample 
preparation
61, 78-81
 have opened the doors for this technology to have an impact in ever 
expanding biological applications. With particular interest for this present work, spatial 
resolution advancements have been necessary for imaging of small tissue structures such 
as the glomerulus. Resolution of most reported MALDI imaging experiments is in the 
range to 30-200 µm. A push to higher resolution has involved development of both the 
instrument laser technology and sample preparation techniques. One of the major 
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challenges for achieving high resolution images of biological tissue sections is sample 
preparation in terms of matrix deposition methods, matrix crystal size, and sensitivity. 
For example, use of a solvent to aid in the deposition of the MALDI matrix onto a tissue 
section may contribute to analyte delocalization and formation of crystals >20 μm 
limiting the usefulness of a <10 μm beam.  
Summary and Research Objectives 
DN leads to progressive decline in renal function and is the leading cause of end-
stage renal disease. Much still remains unknown about the pathogenesis of this complex 
disease. This project investigates the molecular changes that take place in kidney 
glomeruli and tubules to explore the pathogenic mechanisms of this disease by use of 
MALDI IMS. The first goal of this research project was to develop MALDI MS methods 
for direct tissue analysis of glomeruli within a kidney cortex by imaging mass 
spectrometry and histology directed profiling techniques. The small size of the 
glomerulus had previously made MALDI IMS of this tissue structure a challenge; 
however, advances in imaging resolution and sample preparation have made this 
accessible. These methods have now been applied to study an experimental mouse model 
(eNOS
-/-
 db/db) of diabetic nephropathy. This is one of the most robust models; 
mimicking the progressive functional and structural damage documented in human DN. 
Kidneys from three experimental groups have been studied: wild type (non-diabetic), 
eNOS
-/-
 db/db (diabetic), and pyridoxamine (PM) treated eNOS
-/-
 db/db mice. PM, a 
promising drug candidate for the treatment of DN and an inhibitor of AGE pathways, has 
been shown to have a renal protective effect in Phase II clinical trials. In this work, 
changes in different classes of biomolecules including proteins and lipids have been 
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investigated with specific signatures found in diseased and healthy kidneys. Determining 
biomolecules that undergo change in disease conditions and evaluating response to 
treatment may lead to new molecular markers of disease, provide insight into disease 
pathogenesis, and characterize treatment response. 
The purpose of this work was to achieve the following goals: 
Objective 1: Develop methods for direct tissue analysis of kidney micro-structures 
including the glomerulus and tubules. 
Objective 2: Assess the biological significance of lipid changes and their spatial 
distributions in healthy and diabetic kidneys and evaluate the response of lipid signatures 
in disease after treatment with PM, an inhibitor of oxidative and glycoxidative reactions.  
Objective 3: Assess the biological significance of protein changes and their spatial 
distributions in healthy and diabetic kidneys and evaluate the response of protein 
signatures in disease after treatment with PM. 
 
 
 
  
22 
 
CHAPTER II 
 
METHODS FOR HIGH SPATIAL RESOLUTION IMAGING AND TARGETING 
OF MICROSTRUCTURES IN THE KIDNEY WITH MASS SPECTROMETRY  
 
Overview 
This chapter will describe the application and use of MALDI IMS with specific 
considerations and procedures required for kidney analysis. Two common workflows of 
MALDI IMS will be described: the histology directed workflow and the imaging 
workflow. These general workflows have been described previously
56, 66, 82, 83
 but 
presented here are specific considerations for sample preparation and instrumentation for 
high spatial resolution imaging to target microstructures of the kidney including specific 
tubular and glomerular structures. In this work high spatial resolution is defined by 
imaging at ≤25 µm. Specific procedures for both lipid and protein analysis will be 
presented.   
MALDI IMS as a Tool to Study Kidney Disease 
Innovation and new technology enable advancements in medical and biological 
research. Despite the significance of glomerular diseases, there is still incomplete 
understanding of the underlying pathogenic mechanisms. Uncovering molecular events 
that define mechanisms of susceptibility and progression in glomerular pathology such as 
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DN will require novel research technologies. MALDI IMS is one such technology that is 
being utilized in kidney research. 
Direct kidney tissue analysis by MALDI MS has been used in previous studies of 
kidney diseases in both humans and animal models of disease.
84, 85
 MALDI IMS of 
human kidney biopsies from renal cell carcinoma patients has shown molecular margins 
between tumor and normal kidney that differ from histological margins.
86
 Groups have 
used this technology in animal models to study polycystic kidney disease,
69
 
glycosphingolipid storage disease,
87
 immunoglobulin A nephropathy,
88
 and drug 
distribution within a kidney section after dosing.
68, 70
 Specific to the glomerulus, laser 
capture microdissection has been used to isolate glomeruli from kidney sections and 
profile pooled glomeruli with MALDI MS in a rat model of focal segmental 
glomerulosclerosis.
89
 None of these studies however has shown molecular changes at the 
level of single glomerulus within a kidney section. In this chapter, we demonstrate the 
use of MALDI IMS to analyze the molecular composition of single glomeruli and tubules 
within the kidney cortex. 
MALDI IMS Overview 
MALDI IMS acquires molecular information in a spatially defined manner. There 
are two general workflows that can be followed in a MALDI IMS experiment: the 
traditional imaging workflow and the histology directed workflow. Each has utility in 
analysis of kidney glomeruli and involves careful tissue preparation and matrix 
application steps before analysis in the mass spectrometer. Each aspect will be described 
in more detail later in this chapter but the general steps of the two workflows are as 
follows. In the imaging mode (Figure 2.1), a chemical matrix to aid in the absorption of  
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Figure 2.1. Schematic representation of IMS analysis of kidney sections.   Frozen kidneys 
are cryo-sectioned at 10 μm and thaw-mounted on a glass slide. A thin coating of the 
MALDI matrix is applied across the entire tissue section by sublimation. An ordered 
array is set up across the kidney section and the MALDI laser is directed at each pixel to 
acquire a mass spectrum at every point. Molecular images are then constructed by 
selecting m/z values in the spectra to determine where different molecules are localized 
throughout the kidney section.  Artificial color scale is used to indicate differences in 
signal intensity for each m/z value. 
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laser energy is applied uniformly over the sample.  The laser is moved in a raster pattern 
and a spectrum is collected at every pixel in an ordered array across the tissue.  Data can 
then be displayed as molecular maps of the spatial localization of given m/z values 
throughout the tissue.  If required, molecular identification can be performed directly on 
the tissue section by MS/MS analysis. In the histology-directed mode (Figure 2.2), 
classical histology guides the analysis of specific regions of the tissue.  First, a chemical 
matrix is applied in the discrete areas of interest within the tissue section. A laser beam is 
used to irradiate the matrix and ionize tissue molecules. As the result, the mass-to-charge 
ratio of each detected molecule is assigned to a corresponding spatial location within the 
tissue section. Each workflow requires the basic steps of tissue sectioning, matrix 
application and mass spectrometry analysis.  
As with any methodology, MALDI IMS also has specific limitations. Analysis 
comes directly from a tissue section where a high concentration of salts and major plasma 
proteins may interfere with detection of other molecules of interest. Tissue washing can 
often be successfully used to reduce this interference.
75, 90
 Also, with MALDI IMS there 
are no upstream separation steps which could help increase the depth of coverage. Other 
MS techniques such as ion mobility MS or LC/MS can be used in conjunction with IMS 
to address these shortcomings.  It is important to note that up-stream pre-separation 
procedures may also introduce artifacts thus complicating sample analysis. Further, 
MALDI IMS involves the addition of a chemical matrix to the tissue section.  The choice 
of MALDI matrix influences what is detected, with certain matrices favoring certain 
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Figure 2.2. Schematic representation of histology directed profiling. (A) A fresh frozen 
kidney is cryo-sectioned at 10 um and thaw-mounted on an ITO glass slide. The kidney 
section is stained with cresyl violet (a MALDI MS compatible stain) for visualization of 
the glomeruli. (B) Position of glomeruli is determined using MIRAX Viewer, indicated 
by red dots. The coordinates are exported to the robotic spotter. (C) The robotic spotter 
deposits trypsin at selected glomeruli for in situ digestion followed by the MALDI matrix 
at the same locations. (D) The sample is inserted in to the mass spectrometer and the laser 
fires at the matrix covered glomeruli producing ions from individual glomeruli.  
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classes of molecules.  On the other hand, careful matrix choice or use of different 
matrices in parallel sample analyses can enhance detection of analytes of interest. 
Given the limitations, there are also many advantages with this technology. 
MALDI IMS involves minimal tissue processing, and there is little dilution effect, when 
compared with other proteomic technologies such as laser capture microdissection or 
whole tissue homogenization followed by LC/MS. Unlike immunohistochemical 
analysis, the knowledge of protein identities prior to the analysis is not required, there is 
no need for any target-specific reagents, and there are no issues with hidden epitopes for 
antibody binding. In a single experiment, potentially hundreds of molecules can be 
analyzed from spatially discrete regions of a single tissue section, making MALDI IMS 
technology an invaluable discovery tool.   
There are many aspects to consider in a MALDI imaging experiment including 
tissue preparation, matrix application, image size and resolution, instrumentation and data 
analysis. The following will discuss each of these aspects.   
Fresh Frozen Tissue Preparation 
Sample collection, freezing, and sectioning 
MALDI IMS can be applied to fresh frozen tissue as well as FFPE tissue. Use of 
fresh frozen tissue allows for robust analysis of a variety of molecules including drugs, 
metabolites, lipids, and proteins. However, FFPE tissue comprises a large portion of what 
is stored in tissue banks which can be a valuable source of samples. As such, methods 
have been developed for MALDI IMS of FFPE tissue
64, 91
 but studies are generally 
limited to enzymatically digested peptides. Fresh frozen tissue was used for all analyses 
in this study and will be the focus of the methods described in this chapter. 
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At the time of procurement, organs should be removed and immediately flash 
frozen in liquid nitrogen to limit degradation of tissue molecules. When doing animal 
studies, this can and should be controlled; however for samples such as human biopsy or 
tissue resection the researcher may not be able to control the procurement conditions as 
tightly. It is best to freeze organs in a way that will best maintain the original shape. This 
can be done by placing the organ on aluminum foil shaped as a boat and slowly lowering 
it into the liquid nitrogen. The tissue should completely freeze in a few minutes and can 
then be transferred to a -80°C freezer for storage. Organs stored at -80°C can be 
preserved for analysis for several years with minimal degradation.  
Tissues stored at -80°C are warmed to -20°C for sectioning on a cryostat. Frozen 
tissues are usually sectioned between 8 and 20 µm thickness. After a section is cut it 
should be manipulated carefully with a fine brush, positioned onto a cooled MALDI 
target, and then thaw mounted to adhere to the target by placing a warm thumb or finger 
under the target where the tissue was placed. The MALDI TOF instruments used in this 
study require target plate conductivity. Gold coated metal targets and indium tin oxide 
(ITO)-coated microscope glass slides are two common conductive surfaces used. Metal 
targets are often used as a sample substrate because of their high conductivity. When 
these are used, a section serial to the analysis section is cut and mounted on a glass slide 
for histological staining allowing for co-registration of histological features with the 
molecular signals detected. However, for small histological features such as the 80 µm 
glomeruli in the mouse kidney, it is difficult to track the same structures in a serial 
section and it is best to use the same section for mass spectrometry analysis and 
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histological staining. For this reason, conductive ITO slides were used for all applications 
in this work.   
Tissue washing 
It is often advantageous to wash a tissue section before matrix application and 
analysis. Many tissues, and kidneys in particular, contain many salts that can contribute 
to signal suppression with MALDI MS. The washing procedure is, of course, dependent 
on the molecules of interest that are to be analyzed. The two major classes of molecules 
studied in this work are proteins and lipids and each requires a unique tissue preparation. 
Procedures that have been found to work well for kidney analysis of both lipids and 
proteins are described below.  
Lipids are abundant molecules on the tissue surface. In many cases, no additional 
washing steps are required and the matrix can be applied directly after sectioning for 
MALDI MS analysis. Recent work by Angel et al.
76
 has shown that using an aqueous 
wash with a volatile buffer can enhance the sensitivity of lipids detected from the tissue 
surface, in part by removing salts and reducing matrix clusters. Based on this report, an 
ammonium formate wash was found useful for the lipid experiments conducted for 
kidney imaging in this work. This wash for lipid enhancement was done by dipping the 
sample slide in 50 mM ammonium formate at 4°C three times for five seconds followed 
by desiccation prior to matrix application. 
Proteins can also be detected from a tissue sections without any wash, however, 
due to the high concentration of lipids and salts in the tissue, suppression of the MALDI 
MS signal is often observed. A common wash documented in the literature for protein 
studies uses a graded ethanol series. For high spatial resolution imaging in the kidney, it 
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was found that a more stringent wash was necessary to remove the lipids to increase 
sensitivity for protein detection. Given this, kidney sections were processed using a 
washing procedure described by Yang et al.
81
 Specifically, the sample slide was 
immersed in 70% ethanol for 30 s, 100% ethanol for 30 s, Carnoy’s fluid for 2 m, 100% 
ethanol for 30 s, water for 30 s, and then 95% ethanol for 30 s.  
Matrix Application for Micro-Structure Analysis 
Matrix Deposition Methods for Imaging 
A major issue for achieving high resolution images of biological tissue sections 
with MALDI MS is sample preparation. Appropriate sample preparation methods will 
create a fine, uniform, and densely packed matrix crystal surface that has sufficient 
sensitivity for the analytes of interest. Current matrix application methods for protein 
analysis involve spraying or spotting the matrix in a solvent solution on to the tissue 
section. The solvent aids in the extraction of proteins and peptides from the tissue, which 
then co-crystallize with the matrix on the sample surface, and increase the availability of 
these analytes for detection. However, applying the matrix in a solvent solution in this 
way may contribute to analyte delocalization and formation of crystals >20 μm, limiting 
the usefulness of a <10 μm laser beam for high spatial resolution imaging. Figure 2.3A 
shows crystals formed using micro-spotting and spraying matrix dissolved in solvent. 
Micro-spotting involves deposition of matrix droplets in an array with a robotic spotter. 
Imaging resolution is thus limited by the size of the dried droplets and the pitch in which 
they are spotted (typical resolution ≥150 μm). Spraying the matrix has the advantage of 
continuous matrix coverage across the sample, but crystals tend to be larger than 25 μm 
and there are gaps on the order of 15 μm. The large crystals and gaps introduce imaging 
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Figure 2.3. Optical and SEM analysis after MALDI matrix deposition. (A) Optical 
images of matrix crystals applied by microspotting, spraying, and sublimation. Scale bar 
= 100 μm. (B) SEM micrographs of sublimated DHB, SA, and CHCA on a gold plate. 
Sublimated matrix layers lack gaps in the surface and the crystals are on the order of 1 
μm. Scale bar = 10 μm. 
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artifacts when the laser spot size is on the order of or smaller than these features. Matrix 
deposition by sublimation has overcome the crystal size and coverage problem for lipid 
analysis by producing a uniform and fine grain size of the matrix.
61
 As seen in the optical 
image and the SEM micrographs in Figure 2.3, sublimation produces uniform and 
complete matrix coverage and crystals on the order of 1 μm. SEM micrographs of three 
commonly used MALDI matrices are shown for demonstration. Sublimation was first 
introduced as a method of matrix deposition for imaging by Hankin et al. in 2007. 
However, due to the dry coating conditions this method was limited to analysis of lipids 
which are abundant on the tissue surface. Proteins were not detected with this solvent-
free preparation method, presumably due to lack of sufficient contact between the 
proteins within the tissue and the matrix deposited on the surface. A method was recently 
published that involves recrystallization of a sublimated matrix on plate spotted 
samples.
80
 The recrystallization process retained the small crystal size produced by the 
sublimation but was able to detect peptides with increased sensitivity. This concept has 
been extended to tissue imaging applications for the detection of peptides and proteins. A 
spectrum from a single pixel acquired from a kidney sublimated with CHCA followed by 
rehydration is displayed in Figure 2.4 showing detection of protein signals. Without 
rehydration no protein signal was detected. With sublimation now amenable to both lipid 
and protein imaging, high spatial (≤ 25 μm) resolution is now achievable for both of these 
classes of molecules. 
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Figure 2.4. Protein IMS at high spatial resolution. The optical image shows the MALDI 
laser ablation regions from a sublimated/rehydrated CHCA matrix coating. The spectrum 
displayed is from a single pixel in the image. Scale bar = 10 um. 
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Matrix Choice for Lipids and Proteins 
While hundreds of compounds have been tested for use as MALDI matrices, only 
a handful are used for most applications. As discussed in the previous section, matrix 
deposition by sublimation was found to be necessary for the spatial resolution required 
for imaging glomeruli and tubules in the mouse kidney. In Table 2.1, matrices and their 
sublimation conditions are listed that were found to produce high quality signal in the 
kidney.  
For many reported lipid studies 2,5-dihydroxybenzoic acid (DHB) has been a 
widely used matrix but, recently, 1,5-diaminonaphthalene (DAN) has garnered more 
attention due to its high sensitivity in both positive and negative mode.
92
 Figure 2.5 
shows an average spectrum from serial kidney sections prepared with DAN or DHB. The 
spectra were collected using the same laser and instrumental conditions and the signal 
intensity increased approximately an order of magnitude with DAN compared to DHB in 
both positive and negative mode. As laser spot sizes get smaller, the sample ablation area 
(and thus number of molecules ablated) gets smaller as well so the increased sensitivity 
that DAN yields is especially important at high spatial resolution. DAN has been found to 
produce high quality lipid spectra with laser spot sizes at 10 μm down to even 2 μm, 
which is the smallest laser beam used in this work. In Figure 2.6, a kidney cortex is 
imaged at 10 μm spatial resolution for lipids with DAN displaying a number of unique 
kidney structures with specific lipid patterns. While DAN has been found to produce high 
quality spectra for many phospho- and glyco- lipids, surveying of matrices for best 
sensitivity is recommended particularly if a specific analyte of interest is being targeted. 
For example, in this work, we were interested in detecting glucose modified 
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Matrix                         
(Abbr.) 
Formula 
MW 
(Da) 
Structure 
Sub 
T  
(°C) 
Sub 
Time 
(min) 
Use 
2,5-dihydroxybenzoic 
acid                                            
(DHB) 
C7H6O4 154.026 
 
110 7 lipids 
1,5-
Diaminonaphthalene 
(DAN) 
C10H10N2 158.084 
 
110 7 lipids 
9-Aminoacridine                   
(9-AA) 
C13H10N2 194.084 
 
150 12 lipids 
2,5-
Dihydroxyacetophenone 
(DHA) 
C8H8O3 152.047 
 
105 6 
lipids, 
proteins 
α-Cyano-4-
hydroxycinnamic acid 
(CHCA) 
C10H7NO3 189.042 
 
135 30 
peptides, 
proteins 
Sinapinic Acid                          
(SA) 
C11H12O5 224.068 
 
120 18 proteins 
Table 2.1. Matrices and sublimation conditions used for high spatial resolution IMS. 
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Figure 2.5. Comparison of DAN and DHB as a matrix for kidney lipid analysis. Negative 
mode (A) and positive mode (B) spectra from a kidney cortex comparing DAN matrix 
(blue) and DHB matrix (red). The same laser and instrumental conditions were used for 
both matrices. 
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Figure 2.6. 10 μm resolution lipid imaging with DAN. (A) Selected ion images showing 
lipid localization in micro-structures of the kidney cortex. (B) Spectra selected from 
regions of the kidney where the color of the spectrum corresponds to the region from 
panel A with the same color.  
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aminophospholipids (i.e.- phosphatidylethanolamine (PE), described in chapter 3) which 
were suspected to be present in diabetic tissue. Use of DAN did not detect any glucose 
modified PEs in the kidney tissue but 9-aminoacridine (9-AA) increased the sensitivity of 
detection for this class of molecules. It should also be noted that while negative mode 
MALDI MS of lipids typically produces [M-H]
-
 ions, the use of both 9-AA and DAN can 
produce [M-CH3]
-
 ions of phosphatidylcholine (PC) and sphingomyelin (SM) species, 
lipids usually detected in positive mode due to their permanent positive charge.
93, 94
 
These [M-CH3]
-
 ions can overlap in mass with [M-H]
-
 ions of PEs so care needs to be 
taken to distinguish these classes when making lipid assignments.     
For protein and peptide analysis, sinapinic acid (SA) and α-cyano-4-
hydroxycinnamic acid (CHCA) are the most commonly used compounds. These matrices 
were able to be sublimated on to a tissue surface but no protein signal could be detected 
with sublimation alone. As mentioned above, a rehydration step was found to be 
necessary to produce peptide and protein signal from matrix sublimated on a tissue 
surface. Rehydration is accomplished in a sealed petri dish containing 1 mL of 5% TFA 
at 85°C for 3.5 minutes. Sublimation/rehydration is suitable for high spatial resolution 
IMS of proteins as can be seen in the 25 μm image in Figure 2.7. Protein signals specific 
to the glomerulus are displayed.  
Matrix Deposition for Histology Directed IMS to Target Glomeruli 
Histology-directed MALDI MS is an approach to imaging that combines 
histological information with robotics to target specific tissue regions. This method is 
advantageous in that it is targeted and much faster than imaging an entire tissue section. 
Histology-directed IMS has been previously described,
66
 but some specific modifications 
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Figure 2.7. 25 μm resolution protein imaging with sublimated/rehydrated CHCA. Protein 
signals specific to the glomerulus are displayed. 
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to the published procedure are necessary to target glomeruli. Previous work used a 
histology stain on a serial section to guide the coordinate selection for analysis. However, 
targeting glomeruli requires use of the same section for both identification of tissue 
features (i.e. - glomeruli) and MALDI MS analysis. This is demonstrated in Figure 2.8A 
where it can be seen that a glomerulus observed in one section may not be present in the 
serial section. Additionally, while many glomeruli do track from one section to the next 
one, the relative positions of each translate differently in space with respect to another. 
Serial sections are often used because many common histology stains (such as H&E and 
PAS) interfere with MALDI MS signal. However, certain stains have been found to be 
compatible with MALDI MS such as cresyl violet.
95
 Though this stain does not give as 
much histological information as H&E or PAS, it provides enough contrast to pick out 
glomeruli structures. Kidney sections mounted on an ITO glass slide can be stained with 
0.5% cresyl violet for 30 s followed by an ethanol rinse for 15 s to aid in distinguishing 
the glomeruli under a microscope. After scanning the sample slide, the glomeruli can be 
identified and their coordinates recorded with respect to a set of fiducials on the MALDI 
slide. These coordinates can then be transferred to the automated acoustic robotic spotter 
(Portrait 630, Labcyte). In addition to spotting MALDI matrix, this robotic spotter can 
also deposit picoliter volumes of trypsin for in situ enzymatic digestion of proteins before 
matrix spotting.
96
 In this way, MALDI MS/MS can be performed on peptides from these 
spots for identification of proteins. In this work, trypsin solution (76 ng/µL trypsin in 100 
mM ammonium bicarbonate/10% acetonitrile) was spotted on the selected glomeruli in 
single droplets (~120 pL) for a total of 40 iterations allowing each droplet to dry for two 
minutes before spotting the next droplet. Proteolytic digestion was allowed to take place  
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Figure 2.8 Glomerulus analysis with histology-directed profiling. (A) PAS stain of serial 
sections showing glomeruli. Glomeruli circled in yellow and green represent the same 
glomerulus in each section. The glomerulus circled in black is not found in the serial 
section demonstrating that the same section for picking coordinates (i.e. glomeruli) needs 
to be used for MS analysis. (B1) Cresyl violet stained glomerulus from eNOS
-/-
 db/db 
kidney section. (B2) MALDI MS spectrum of tryptic peptides from a selected 
glomerulus; peptide at m/z 1198 was sequenced using tandem MS mode. (B3) Tandem 
MS (MS/MS) spectrum and corresponding amino acid sequence of the peptide at m/z 
1198; the peptide was identified as a tryptic fragment of actin by searching the mouse 
SwissProt database with MASCOT software. 
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for approximately two hours. Subsequently, MALDI matrix (10 mg/mL CHCA in 1:1 v/v 
mixture of acetonitrile and 0.2% trifluoroacetic acid) was robotically spotted on the 
trypsin digested glomeruli. An example of a spectrum from a single glomerulus is shown 
in Figure 2.8B. This type of workflow allows for protein identification directly from the 
tissue section by MS/MS fragmentation of the tryptic peptides along with database 
searching. 
MALDI MS Instrumental Considerations for Direct Kidney Analysis  
Imaging Resolution Considerations  
 The spatial resolution of an imaging experiment is most simply determined by the 
size of the laser beam spot on target and the pitch, or step size of the stage, between laser 
ablation spots. However, in practice, this is also dependent on the matrix crystal size. 
Lenses and improved optics have been used to focus the laser beam on the target. The 
commercial instruments used in this study can achieve a spot size of ~10 µm. However, 
others have achieved smaller laser spot sizes with special lenses with a co-axial laser 
beam path
52
 and laser beam filtration with a pinhole.
74
 It is possible to image at a higher 
spatial resolution than the size of the laser beam using a technique is called oversampling. 
In oversampling, the matrix is completely ablated in an area and then the stage is moved 
a distance smaller than the ablation spot but enough so fresh material is available for 
ablation. While this has been used with some success, often it results in degradation of 
signal quality.  
While increasing spatial resolution allows one to resolve smaller features and 
structures in a tissue section, there is a tradeoff. One has to consider the size of the 
features of interest, the time of the experiment, the size of the data and the sensitivity 
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required. In general, smaller spot sizes ablate less material and therefore the sensitivity 
goes down. One structure of interest in this study is the glomerulus. In humans this is 
~200 μm, but in the mouse, the model used in this study, it is only ~80 μm (Figure 2.9A). 
To adequately reconstruct ion images of a mouse glomerulus, a minimum of 50 µm 
spatial resolution has been found to be necessary but ≤ 30 µm is more desirable. While 
decreasing the pixel size increases the resolution of the glomerulus, it also increases the 
time of analysis and the data size if you are to image the same unit area. The number of 
pixels (i.e. number of spectra) is a square function of step size. As can be seen in Figure 
2.9B, reducing the laser spot size from 100 µm to 25 µm (a factor of 4) increases the 
number of pixels (spectra) by 16 times. 
Instrumentation for Imaging 
MALDI sources can be interfaced with a number of different mass analyzers. In 
this work MALDI TOF and MALDI FTICR mass spectrometers are the main instruments 
used and the fundamentals of each have been described in Chapter I. As a general 
guideline, protein imaging is typically performed using linear TOFs and lipid imaging is 
most often done using reflectron TOFs and FTICR instruments where higher mass 
resolution is needed. In general, a linear TOF is the preferred instrument for protein 
imaging due to its speed, sensitivity, and theoretically unlimited mass range. In practice 
however, sensitivity and resolution cannot be optimized for all m/z values across a large 
mass range so instrument tuning is usually performed to optimize for given mass range. 
A Bruker Ultraflextreme MALDI TOF mass spectrometer equipped with a Smartbeam 
laser was the major instrument used for both lipid and protein imaging in this work. 
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Figure 2.9. Spatial resolution considerations for IMS of glomeruli. (A) Comparison of 
size between a mouse glomerulus and a human glomerulus. (B) Schematic representation 
of how the laser spot size (and therefore resolution) affects the number of pixels acquired 
per glomerulus.  
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Protein imaging was performed using linear mode in the range of m/z 1,000 - 25,000 at a 
spatial resolution of 25 µm. Lipid imaging was performed on the same instrument in 
reflectron mode in the range of m/z 400 - 1,500 at a spatial resolution of 10 µm.  
A MALDI FTICR MS was used in parallel to the TOF imaging experiments. 
Profiling and imaging experiments were performed on a 9.4T and 15T Bruker SolariX 
FTICR MS to obtain accurate mass measurements for ions of interest which assisted in 
the identification. In addition to high mass accuracy measurements, data can be acquired 
in continuous accumulation of selected ion (CASI) mode to increase the sensitivity of an 
experiment. In this mode, a selected m/z range is filtered in the quadrupole and 
accumulated in a hexapole before being sent into the ICR cell. By removing high 
intensity ions from other regions of the spectrum, low abundance species can be 
accumulated with a number of laser shots (hundreds to tens of thousands) before FTICR 
detection. Figure 2.10 demonstrates the increase in sensitivity and signal to noise across 
the lipid range in negative mode with CASI, where each color in Figure 2.10B represents 
a single CASI analysis. In this work CASI was utilized in the initial experiments that 
found glucose modified lipids in diabetic kidneys. This feature was also used extensively 
for lipid identification to increase the signal intensity of the parent ion before 
fragmentation. 
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Figure 2.10. Sensitivity increase using CASI. (A) Standard full spectrum FTICR MS scan 
in negative ion mode. (B) Combined CASI spectra overlaid across the same mass range 
as in (A). Each color represents a single spectrum collected with a narrow mass window. 
Using CASI results in increased sensitivity and signal to noise as seen in the inset regions 
of (A) and (B).   
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Data Processing, Image Co-registration, and Image Analysis 
Spectral Pre-processing 
 Spectral pre-processing is an important first step in analyzing imaging datasets. 
Pre-processing reduces experimental variance so that spectra within a single dataset and 
across multiple datasets can be better compared. Mass spectra are processed by 
background subtraction, normalization, and spectral realignment.
97
 This helps reduce 
chemical noise, day to day instrument variations and signal intensity differences due to 
matrix coating. This not only allows for better comparison of expression differences 
between spectra but also increases image quality by increasing contrast and compensating 
for matrix inhomogeneity.  
Histological Staining and Image Co-registration 
 After an imaging experiment is completed, the matrix can be washed off of the 
tissue section in a series of graded ethanols to allow for histological staining. H&E stain 
is a common and versatile stain that is often used. PAS is a stain of choice for kidney 
disease as it shows extracellular matrix build-up. After staining, the slide can be scanned 
and then the histology of the same section that was imaged with MS can be co-registered 
together to map ions of interest to specific structures within in the tissue section. This is 
particularly helpful for small tissue structures where it is difficult to find the 
corresponding histology without an overlay or in a serial section. Figure 2.11 shows an 
example of a co-registered PAS stain with the IMS data where specific lipid species can 
be seen to localize to specific kidney structures of glomeruli and tubules. 
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Figure 2.11. Co-registration with histology. Above is an example of several selected ion 
signals overlaid which show localization to distinct tissue structures. The PAS stained 
image on the left is the same section that the 10 μm IMS data was collected on. Ion image 
overlay displaying m/z 687.5 (red), m/z 896.6 (cyan), m/z 906.6 (white), and m/z 996.6 
(green).  
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Data Analysis and Relative Quantitation with ImageJ 
For MALDI imaging datasets, ImageJ software (National Institutes of Health, 
Bethesda, MD, USA) was used for relative quantitation of the lipid and protein species of 
interest. Monochromatic TIFF images were exported from FlexImaging to ImageJ. Areas 
of interest were selected in each image as individual glomeruli, tubules, or the entire 
kidney section. Signal intensity was measured as the mean intensity per area of interest. 
The general workflow for the ImageJ processing of ion images is shown in Figure 2.12. 
The mean and standard error were calculated for each MS peak of interest across the 
experimental groups. Differences were evaluated by the Kruskal-Wallis rank-sum test. 
Differences were considered statistically significant if p values were less than 0.05. 
Conclusions 
As demonstrated in this chapter, it is now possible to analyze the molecular 
composition in distinct renal tissue regions and even within smaller structures, such as 
individual renal glomeruli and tubules.  In the following chapters these methods and 
workflows were applied to elucidate molecular changes under conditions of DN and 
examine the effect of a drug treatment.  Chapter III will focus on changes in the lipid 
composition while Chapter IV will present findings on protein composition and changes 
in the kidneys of different experimental groups.   
 
 
 
 
50 
 
 
Figure 2.12. Workflow of ion image analysis with ImageJ. 
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Chapter III 
 
DIABETIC NEPHROPATHY INDUCES ALTERATIONS IN THE 
GLOMERULAR AND TUBULE LIPID PROFILES 
 
Overview 
Diabetic nephropathy (DN) is a major life-threatening complication of diabetes. 
Renal lesions affect glomeruli and tubules but the pathogenesis is not completely 
understood. Phospholipids and glycolipids are molecules that carry out multiple cell 
functions in norm and disease and their role in DN pathogenesis is unknown. We 
employed high spatial resolution matrix-assisted laser desorption/ionization imaging 
mass spectrometry (MALDI IMS) to determine lipid changes in kidneys of eNOS
-/-
 db/db 
mice, a robust model of DN. Phospholipid and glycolipid structures, localization patterns, 
and relative tissue levels were determined in individual renal glomeruli and tubules 
without disturbing tissue morphology. Significant increase in the levels of specific 
glomerular and tubular lipid species from four different classes, i.e. gangliosides, 
sulfoglycosphingolipids, lysophospholipids, and phosphatidylethanolamines, were 
detected in diabetic kidneys compared to non-diabetic controls. Inhibition of non-
enzymatic oxidative and glycoxidative pathways attenuated the increase in lipid levels 
and ameliorated renal pathology, even though blood glucose levels remained unchanged. 
Our data demonstrate that the levels of specific phospho- and glycolipids in glomeruli 
and/or tubules are associated with diabetic renal pathology. We suggest that 
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hyperglycemia-induced DN pathogenic mechanisms require intermediate oxidative steps 
that involve specific phospholipid and glycolipid species. 
Introduction 
Diabetic nephropathy (DN) can develop in about 1/3 of diabetic individuals and 
is characterized by specific glomerular and tubular lesions in the kidney. These lesions 
are associated with progression to end stage renal disease with subsequent requirement 
for renal dialysis and transplantation.
2
 Despite the significance of DN, there is still 
incomplete understanding of the pathogenic mechanisms, particularly those underlying 
the differential susceptibility to DN.   
Lipids may play a role in DN, but to date, the research focus has been on neutral 
lipids such as triacylglycerols and cholesterol.
98
  Phospho- and glycolipids are two major 
classes of lipid molecules that carry out many biological functions ranging from 
regulation of physical properties of cellular membranes to cell signaling.
99, 100
  In 
diabetes, changes in the levels of these lipids in blood and tissues cause dysregulation of 
different cellular processes associated with pathogenesis.
99, 101-105
 Thus, phospho- and 
glycolipids may have a role in DN.   
 The present study is the first report of the application of MALDI IMS to 
investigate molecular changes in renal glomerular and tubular phospho- and glycolipids 
in DN.   We utilized a set of experimental tools: a robust DN mouse model, which 
develops renal lesions comparable to those found in human disease;
106
 a high spatial 
resolution MALDI IMS technology; and pyridoxamine (PM), which was employed to 
elucidate whether hyperglycemia induced oxidative pathways play a role in phospho- 
and glycolipid changes relevant to DN.  PM is an inhibitor of oxidative and 
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glycoxidative reactions and has been shown to act via sequestration of redox active 
metal ions, scavenging of reactive carbonyl compounds, and scavenging of hydroxyl 
radical both in vitro and in vivo.
21, 28, 107-110
  We also used several different mouse models 
to further assess the association between renal damage and lipid profile.  We determined 
molecular changes at the level of a single glomerulus or tubule, which has not been 
achieved in the previous studies of renal tissues using MALDI IMS.
69, 87, 88
  Our data 
demonstrated that the levels of specific phospho- and glycolipids in glomeruli and/or 
tubules of the kidney are associated with diabetic renal pathology.  Inhibition of 
glycoxidative pathways, without lowering hyperglycemia, ameliorated lipid levels and 
renal lesions.  We suggest that hyperglycemia-induced DN pathogenic mechanisms 
require intermediate oxidative steps that involve phospho- and glycolipids. 
Results 
Renal pathology in the eNOS
-/-
 C57BLKS db/db mouse model of Type 2 DN.  
We employed eNOS
-/-
 C57BLKS db/db mice, the most robust mouse model of Type 2 
DN to date.  At >20 weeks of age, these mice exhibit albuminuria, arteriolar hyalinosis, 
increased glomerular basement membrane (GBM) thickness, mesangial expansion, 
mesangiolysis, focal segmental and early nodular glomerulosclerosis, and markedly 
decreased glomerular filtration rate.
106
  In our study, eNOS
-/-
 C57BLKS db/db mice 
developed significant albuminuria at 6 weeks of age which increased dramatically by 22 
weeks of age (Figure 3.1A).  Treatment of diabetic mice with PM significantly 
ameliorated albuminuria at 22 weeks of age (Figure 3.1B). Kidneys of three animals from 
each treatment group were isolated and subjected to MALDI IMS analyses of lipids.  
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Figure 3.1. Urinary albumin-to-creatinine ratio (ACR) in diabetic mice and effect of PM 
treatment. (A) Urinary albumin-to-creatinine ratio in diabetic mice of different age. 
Urinary ACR was determined in non-diabetic control group and in diabetic group at the 
indicated age. (B) PM treatment of diabetic mice (400 mg/kg/day) started at 6 weeks of 
age and continued until 22 weeks of age. Urinary ACR in diabetic (DB) and diabetic + 
PM (DB+PM) groups was determined before and at the end of PM treatment; urinary 
ACR in non-diabetic control group was determined at 22 weeks of age. Each bar graph 
represents the mean ± SEM (n=8). N.S. – not significant. 
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Blood glucose levels and renal pathology data for these mice are presented in Figure 3.2.  
Diabetic mice exhibited dramatic increase in glomerular and tubular pathologic lesions; 
PM treatment significantly ameliorated these lesions (Figure 3.2B-E). Interestingly, PM 
treatment did not inhibit hyperglycemia itself (Figure 3.2A).  Therefore, use of PM 
treatment allowed us to compare renal lipid profiles in hyperglycemic animals with 
significantly different degrees of renal pathology. 
 Composition of mouse renal glomerular and tubular phospho- and glycolipids. 
MALDI IMS was performed on renal sections from three biological replicates in each 
experimental group (non-diabetic, diabetic, and diabetic + PM).  Because DN lesions 
affect primarily glomeruli and tubules, we focused on the lipid molecular patterns 
localized specifically within glomerular and tubular areas of the renal cortex.  We 
examined 60-70 glomeruli and/or tubules per mouse in each experimental group. 
Multiple species that belong to different lipid classes were identified within glomerular 
and tubular structures (Table 3.1).   
 We then focused only on those specific phospho- and glycolipid species that 
exhibited significant changes in glomerular and/or tubular levels in diabetes compared to 
control. These species belonged to four lipid classes: gangliosides, 
sulfoglycosphingolipids, lysophospholipids, and phosphatidylethanolamines and are 
highlighted in Table 3.1. 
 Glomerular levels of major ganglioside NeuGc-GM3 are increased in DN. 
Gangliosides are anionic glycosphingolipids located to the outer leaflet of plasma 
membranes and characterized by the presence of sialic acid in their structure.
111
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Figure 3.2. Renal injury and effect of PM treatment in kidneys. Animal groups and 
treatments were the same as in Figure 1. (A) Blood glucose levels. Correlation between 
tubular basement membrane (TBM) (B) or GBM (C) thickness and albuminuria: non-
diabetic control (triangles), diabetic (circles), and diabetic treated with PM (squares). 
Expansion of renal mesangial matrix (D) and renal sclerosis/fibrosis (E) were scored on a 
scale of 0 to 3 as described under Methods. Sclerosis/fibrosis score is an average of the 
scores for global sclerosis, interstitial fibrosis and vascular fibrosis. Each bar graph 
represents the mean ± SEM. * - p<0.05, diabetic vs. non-diabetic groups; ** - p <0.05, 
diabetic vs. diabetic + PM groups; n=3. 
57 
 
Table 3.1. Composition of mouse renal glomerular and tubular lipids determined by 
direct tissue MALDI MS analysis. Lipids shown in red bold font were detected only in 
diabetic kidneys while the rest were detected in all experimental groups. All lipids were 
identified by MS/MS fragmentation analysis. *- lipid species identified with accurate 
mass and only head group specific fragments. Probable side chains included. 
†
- resulted 
from the decomposition of SB1a during the ionization process.
87, 112
 
Lipid Class Lipid ID 
Theoretical 
m/z 
Ion 
Species 
Error  
(ppm) 
Localization 
I. Phospholipids  
Lysophospholipids 
LPA (18:0) 437.2673 [M-H]
-
 -0.23 Glomerular 
LPC (16:0) 480.3095 [M-CH3]
-
 -0.42 Glomerular 
LPC (18:2) 504.3095 [M-CH3]
-
 -0.40 Glomerular 
LPC (18:0) 508.3408 [M-CH3]
-
 -0.39 Glomerular 
Glycerophospholipids 
PA (18:0/18:1) 701.5127 [M-H]
-
 0.57 Glomerular 
PE (16:0/20:4) 738.5079 [M-H]
-
 0.70 Tubular 
PE (18:1/18:2) 740.5236 [M-H]
-
 0.63 Tubular 
PE (18:2/18:0) 742.5392 [M-H]
-
 0.85 Tubular 
PA (18:0/22:5) 749.5127 [M-H]
-
 0.67 Glomerular 
PE (16:0/22:6) 762.5079 [M-H]
-
 -0.31 Tubular 
PE (18:1/20:4) 764.5236 [M-H]
-
 1.03 Tubular 
PE (18:0/20:4) 766.5392 [M-H]
-
 -0.01 Tubular 
PE (40:8) 786.5079 [M-H]
-
 0.12 Tubular 
PE (18:1/22:6) 788.5236 [M-H]
-
 1.09 Tubular 
PE (18:0/22:6) 790.5392 [M-H]
-
 -0.37 Tubular 
PS (38:3) 812.5447 [M-H]
-
 0.49 Glomerular 
PS (40:5) 836.5447 [M-H]
-
 1.20 Glomerular 
PS (40:4) 838.5603 [M-H]
-
 1.19 Glomerular 
PI (18:0/22:4) 909.5499 [M-H]
-
 -0.22 Tubular 
PI (18:0/22:4) 913.5811 [M-H]
-
 1.42 Glomerular 
Plasmalogens 
PE (P-36:4) 722.513 [M-H]
-
 0.97 
Glomerular, 
tubular 
PE (P-16:0/22:6) 746.513 [M-H]
-
 0.45 
Glomerular, 
tubular 
PE (P-38:5) 748.5287 [M-H]
-
 0.67 
Glomerular, 
tubular 
PE (P-18:0/20:4) 750.5443 [M-H]
-
 0.24 
Glomerular, 
tubular 
PE (P-18:0/22:6) 774.5443 [M-H]
-
 -0.08 
Glomerular, 
tubular 
Sphingophospholipids 
SM (d18:1/16:0) 687.5446 [M-CH3]
-
 1.02 Glomerular 
SM (d18:1/18:0) 715.5759 [M-CH3]
-
 0.00 Glomerular 
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Table 3.1 (continued). 
Lipid Class Lipid ID 
Theoretical 
m/z 
Ion 
Species 
Error  
(ppm) 
Localization 
I. Phospholipids (cont.)  
Glycated    
Phosphatidylethanolamine 
Amadori-PE (P-36:4) 884.5658 [M-H]
-
 -0.97 
Glomerular, 
tubular 
Amadori-PE (36:5) 898.5451 [M-H]
-
 0.56 Tubular 
Amadori-PE 
(16:0/20:4) 
900.5607 [M-H]
-
 -0.33 Tubular 
Amadori-PE 
(18:1/18:2) 
902.5764 [M-H]
-
 0.55 Tubular 
Amadori-PE 
(18:2/18:0) 
904.592 [M-H]
-
 0.55 Tubular 
Amadori-PE (P-38:6) 908.5658 [M-H]
-
 0.28 
Glomerular, 
tubular 
Amadori-PE (P-
18:1/20:4) 
910.5815 [M-H]
-
 1.76 
Glomerular, 
tubular 
Amadori-PE (P-
18:0/20:4) 
912.5971 [M-H]
-
 -0.33 
Glomerular, 
tubular 
Amadori-PE 
(16:0/22:6) 
924.5607 [M-H]
-
 -0.54 Tubular 
Amadori-PE 
(18:1/20:4) 
926.5764 [M-H]
-
 -0.86 Tubular 
Amadori-PE 
(18:0/20:4) 
928.592 [M-H]
-
 -0.32 Tubular 
Amadori-PE (P-40:7) 934.5815 [M-H]
-
 0.21 
Glomerular, 
tubular 
Amadori-PE (P-
18:0/22:6) 
936.5971 [M-H]
-
 -0.11 
Glomerular, 
tubular 
Amadori-PE (40:8) 948.5607 [M-H]
-
 -0.95 Tubular 
Amadori-PE 
(18:1/22:6) 
950.5764 [M-H]
-
 0.21 Tubular 
Amadori-PE 
(18:0/22:6) 
952.592 [M-H]
-
 0.52 Tubular 
II. Glycolipids  
Sulfoglycosphingolipids 
SM4s(d18:1/h20:0) 850.571 [M-H]
-
 0.94 Tubular 
SM4s(d18:1/h22:0) 878.6033 [M-H]
-
 0.23 Tubular 
SM4s(d18:1/h24:1) 904.6189 [M-H]
-
 -0.33 Tubular 
SM4s(d18:1/h24:0) 906.6346 [M-H]
-
 -0.22 Tubular 
SM3(t18:0/20:0)* 1014.6405 [M-H]
-
 -0.10 Tubular 
SM3(d18:1/22:0) 1024.6612 [M-H]
-
 0.20 Tubular 
SM3(d18:1/h22:0) 1040.656 [M-H]
-
 0.29 Tubular 
SM3(t18:0/22:0) 1042.6718 [M-H]
-
 0.86 Tubular 
SM3(d18:1/24:1) 1050.6768 [M-H]
-
 -0.10 Tubular 
SM3(d18:1/24:0) 1052.6925 [M-H]
-
 0.09 Tubular 
SM3(t18:0/h22:0) 1058.666 [M-H]
-
 1.04 Tubular 
SM3(d18:1/h24:1) 1066.671 [M-H]
-
 0.66 Tubular 
SM3(d18:1/h24:0) 1068.6874 [M-H]
-
 0.19 Tubular 
SM3(t18:0/24:0) 1070.7031 [M-H]
-
 0.28 Tubular 
59 
 
 
 
 
 
 
 
Table 3.1 (continued). 
Lipid Class Lipid ID 
Theoretical 
m/z 
Ion 
Species 
Error  
(ppm) 
Localization 
II. Glycolipids (cont.)  
Sulfoglycosphingolipids 
(cont.) 
SM3(t18:0/h24:1) 1084.682 [M-H]
-
 0.92 Tubular 
SM3(t18:0/h24:0) 1086.697 [M-H]
-
 0.18 Tubular 
SM2a(d18:1/22:0)* 1227.7406 [M-H]
-
 -0.57 Tubular 
SM2a(t18:0/22:0)* 1245.7511 [M-H]
-
 -0.16 Tubular 
SM2a(d18:1/24:0)* 1255.7719 [M-H]
-
 1.04 Tubular 
SM2a(d18:1/h24:0)* 1271.7668 [M-H]
-
 -0.94 Tubular 
SM2a(t18:0/24:0)* 1273.7824 [M-H]
-
 0.47 Tubular 
SB1a(t18:0/20:0)* 1379.7727 [M-SO3H]
-
 -0.94 Tubular 
SM1a(t18:0/20:0)*† 1379.7727 [M-H]- -0.94 Tubular 
SB1a(d18:1/22:0)* 1389.7934 [M-SO3H]
-
 0.07 Tubular 
SM1a(d18:1/22:0)*† 1389.7934 [M-H]- 0.07 Tubular 
SB1a(t18:0/22:0)* 1407.804 [M-SO3H]
-
 0.92 Tubular 
SM1a(t18:0/22:0)*† 1407.804 [M-H]- 0.92 Tubular 
SB1a(d18:1/24:0)* 1417.8247 [M-SO3H]
-
 -0.42 Tubular 
SM1a(d18:1/24:0)*† 1417.8247 [M-H]- -0.42 Tubular 
SB1a(d18:1/h24:0)* 1433.8196 [M-SO3H]
-
 -0.70 Tubular 
SM1a(d18:1/h24:0)*† 1433.8196 [M-H]- -0.70 Tubular 
SB1a(t18:0/24:0)* 1435.8353 [M-SO3H]
-
 -0.42 Tubular 
SM1a(t18:0/24:0)*† 1435.8353 [M-H]- -0.42 Tubular 
Gangliosides 
NeuAc-GM3 
(d18:1/16:0)* 
1151.7059 [M-H]
-
 -0.17 Glomerular 
NeuGc-GM3 
(d18:1/16:0)* 
1167.7008 [M-H]
-
 -0.51 Glomerular 
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Gangliosides are known to play major roles in cell-cell and cell-matrix recognition via 
interactions with integrins, matrix proteins and other glycosphingolipids as well as in 
innate immunity, apoptosis and carcinogenesis.
113-115
  We determined renal localization 
and levels of two abundant mammalian gangliosides, NeuAc-GM3 (m/z 1151.7) and its 
hydroxylated derivative NeuGc-GM3 (m/z 1167.7) (Figure 3.3).  Both ganglioside 
species were localized exclusively to renal glomeruli (Figure 3.3A and B).  However, 
there was a distinct difference in the response of these species to our experimental 
treatments.  NeuAc-GM3 was detected at relatively high levels that were not significantly 
different in all treatment groups (Figure 3.3A, top row and 3.3D). In contrast, NeuGc-
GM3 was present at relatively low levels in the glomeruli of non-diabetic animals but 
increased ~8-fold in the glomeruli of diabetic mice (Figure 3.3A, bottom row and 3.3D). 
Diabetic mice treated with PM had significantly lower levels of NeuGc-GM3 compared 
to untreated diabetic mice. (Figure 3.3A, bottom row and 3.3D).  Levels of NeuGc-GM3 
were proportional to the degree of renal damage as determined using 13 week old eNOS
-/-
 
db/db mice (Figure 3.1A and 3.4A) and 22 week old db/db and eNOS
-/-
 mice (Figure 
3.4B).
106
  
Levels of long-chain series sulfoglycolipids are increased within renal tubules 
in DN.  Sulfoglycolipids are produced from glycosphingolipids via addition of one or 
several sulfate esters catalyzed by the enzyme cerebroside sulfotransferase (CST).  
Sulfoglycolipids are essential in such key biological processes as nerve fiber myelination 
and spermatogenesis.
116
  They are also enriched in mammalian kidneys where they have 
been shown to be involved in osmoregulation and acid-base homeostasis.
117, 118
  We have   
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Figure 3.3. Gangliosides NeuAc-GM3 and NeuGc-GM3 show distinct changes in 
diabetic glomeruli. (A) MALDI TOF IMS ion images of m/z 1151.7 (NeuAc-GM3) and 
m/z 1167.7 (NeuGc-GM3) in kidneys from non-diabetic control mice, diabetic mice, and 
diabetic mice treated with PM. MALDI IMS was performed at 10 μm spatial resolution 
and compared with PAS staining of the same section to confirm localization to glomeruli. 
(B) IMS of the signal at m/z 1167.7 and corresponding PAS staining showing the specific 
localization of NeuGc-GM3 to glomerulus. (C) Structures of gangliosides corresponding 
to the signals at m/z 1151.7 and m/z 1167.7 as identified using FTICR MS. The bar graph 
(D) represents Mean ± SEM for three biological replicates per group analyzing 200 
glomeruli total. The average signal per glomerulus was determined in ImageJ and data 
were normalized to non-diabetic NeuAc-GM3. * - p <0.05, diabetic vs. non-diabetic 
groups; ** - p <0.05, diabetic vs. diabetic + PM groups. 
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Figure 3.4. Gangliosides NeuAc-GM3 and NeuGc-GM3 in different mouse models.  
NeuAc-GM3 (m/z 1151.7) and NeuGc-GM3 (m/z 1167.7) were determined in kidneys of 
13 and 22 week old eNOS
-/-
 db/db mice (A), and in 22 week old db/db and eNOS
-/-
 mice 
(B). Imaging was performed using MALDI TOF MS at 15 µm spatial resolution in the 
cortex region of the kidney. 
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identified several species of sulfoglycolipids localized specifically to mouse renal 
tubules: SM4s (sulfogalactoceramide), SM3 (sulfolactoceramide), SM2a 
(gangliotriosylceramide sulfate), and SB1a (gangliotetraosylceramide-bis-sulfate) and 
their different acyl chain derivatives (Table 3.1 and Figure 3.5).  There was a significant 
increase in the levels of sulfoglycolipid species SB1a in diabetic kidneys from 22 wk old 
eNOS
-/-
 db/db mice compared to controls (Figure 3.6A and B). This increase was 
ameliorated in diabetic mice treated with PM (Figure 3.6A and B). Levels of SB1a 
showed an intermediate increase in 13 wk old eNOS
-/-
 db/db and in 22 wk old db/db 
mice; the levels did not increase in non-diabetic eNOS
-/-
 mice (Figure 3.7). In contrast to 
SB1a, levels of SM3, a less polar species that possesses a relatively short sugar chain, 
remained unchanged in the DN model (22 wk old eNOS
-/-
 db/db mice) compared to 
control (Figure 3.6A and B).  Tubular localization of both sulfoglycolipids was confirmed 
by comparing the 10 μm spatial resolution IMS data to a PAS stained image of the same 
section (Figure 3.6C).  Similarly, level of SM4s, another sulfoglycolipid with a short 
sugar chain, was also unchanged in diabetic tubules compared to controls.  Interestingly, 
SM3 and SM4s had very distinct non-overlapping tubular localization patterns (Figure 
3.8). 
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Figure 3.5. Structures of sulfoglycolipids.  
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Figure 3.6. Levels of long-chain series sulfoglycolipids are increased within diabetic 
renal tubules. (A) Spectral region containing sulfoglycosphingolipids from tubular 
regions of non-diabetic, diabetic, and diabetic + PM kidneys. (B) Sulfoglycolipid 
SM3(t18:0/22:0), m/z 1042.7 (cyan), was common to the renal tubules and has similar 
levels in all the treatment groups. Sulfoglycolipid SB1a(t18:0/22:0), m/z 1407.8 (yellow), 
was increased in the tubules of the diabetic kidney and reduced upon PM treatment.  
These ion signals are marked with an arrow of corresponding color in panel A.  (C) IMS 
overlay of the m/z 1042.7 (cyan) and m/z 1407.8 (yellow) ion signals displayed in panel 
B. An ion in red specifically localized to the glomeruli is shown for reference (left panels) 
and the corresponding PAS stained sections are shown in the right panels. Imaging 
performed using MALDI TOF MS at 10 µm spatial resolution. 
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Figure 3.7. Long-chain series sulfoglycolipids in kidneys of different mouse models. 
Sulfoglycolipid SB1a(t18:0/22:0), m/z 1407.8 (yellow) were determined in the tubules of 
13 and 22 week old eNOS
-/-
 db/db mice (A), and in 22 week old db/db and eNOS
-/-
 mice 
(B). Imaging was performed using MALDI TOF MS at 15 µm spatial resolution in the 
cortex region of the kidney. 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
Figure 3.8. Tubular localizations patterns of sulfoglycolipids SM3 and SM4s. (A) 
MALDI IMS ion images of SM4s and SM3 localization in the cortex region of the 
kidney. SM4s(d18:1/h24:0) at m/z 906.6 and SM3(t18:0/24:0) at m/z 1070.7 are shown 
and are representative of other SM4s and SM3 localization. MALDI TOF IMS was 
performed at 10 µm spatial resolution. Scale bar = 500 µm.  (B) PAS stain of the section 
analyzed with IMS and zoom-in of overlay from panel A to show specific tubular 
localization. Scale bar = 50 µm. 
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 Major bioactive lysophospholipids are elevated in renal glomeruli in DN.  
Bioactive lysophospholipids (LPLs) are important signaling and regulatory molecules 
involved in multiple pathogenic pathways including inflammation and fibrosis, key 
features of kidney disease.
119, 120
  However, renal LPL levels in DN have not been 
reported.  We have detected LPL species comprising two major classes, 
lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), in the mouse renal 
glomeruli (Table 3.1). The levels of both LPL classes were significantly increased in 
glomeruli of diabetic mice (Figure 3.9).  Moreover, LPC levels were most prominently 
increased within those individual glomeruli exhibiting higher levels of fibrosis as 
determined by PAS staining (Figure 3.10) and were proportional to the degree of renal 
pathology in different mouse models (Figure 3.11).   Levels were significantly 
diminished in diabetic mice treated with PM (Figure 3.9B-D).  Other LPL classes such as 
lysophosphatidylserine, lysophosphatidylglycerol, and lysophosphatidylethanolamine 
were not detected in our study, possibly due to the sensitivity limits as their reported 
physiological levels in mouse plasma are 2-to-3 orders of magnitude lower compared to 
major LPLs.
120
   
Non-enzymatic modification of phosphatidylethanolamine by glucose is 
increased in the cortex of the DN kidney.  Non-enzymatic adduction of glucose to 
aminophospholipids has been shown to increase in diabetic human plasma and animal 
tissues including kidney.
121, 122
  However, with the exception of diabetic atherosclerotic 
lesions,
123
 the role of glycated lipids in diabetic complications has not been investigated.   
We utilized MALDI IMS to analyze glycation of different 
phosphatidylethanolamine (PE) species in the kidney of a mouse model of DN.  The 
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Figure 3.9. Levels of lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) 
increase in the glomeruli of diabetic kidneys. (A) MALDI TOF IMS images showing 
glomerular localization and levels for representative LPA and LPC species (LPA 18:0) 
and (LPC 18:0).  Distribution of LPA (B) and LPC (C) levels within individual glomeruli 
and summary statistical analyses (D). Data are normalized to non-diabetic LPL signal 
intensity. Each circle in the box plots represents the averaged intensity measurement from 
a single glomerulus as determined in ImageJ. * - p<0.05, diabetic vs. non-diabetic 
groups; ** - p<0.05, diabetic vs. diabetic + PM groups.  
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Figure 3.10. Comparison between the levels of LPC and degree of fibrosis within 
individual renal glomeruli. Upper right: Ion image of lysophosphatidylcholine (LPC 
(18:0)) in diabetic kidney. PAS stain of the same section used for IMS showing increased 
signal in more fibrotic glomeruli (red circles) compared to less fibrotic glomeruli (green 
circles). 
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Figure 3.11. MALDI IMS of lysophosphatidylcholine (LPC) in kidneys of different 
mouse models. The signal at m/z 508 (LPC 18:0) was measured in glomeruli of 13 and 22 
week old eNOS
-/-
 db/db mice (A), and in 22 week old db/db and eNOS
-/-
 mice (B). 
Imaging was performed at 15 µm spatial resolution in the cortex region of the kidney. 
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identities of PE species and their glucose modification (Amadori adduct) were 
determined in renal tissue sections using characteristic fragmentation patterns generated 
by tandem MS (Figure 3.12B).  Unmodified PE species as well as unmodified 
plasmalogen PE species, characterized by the presence of a vinyl ether bond at the sn-1 
position,
124
 did not significantly change in diabetes compared to controls (Figure 3.12A). 
Several Amadori-PE species, containing glucose adducted to the lipid amino 
group, were identified in the diabetic kidneys but were not detected in the non-diabetic 
kidneys (Table 3.1, Table 3.2, and Figure 3.12A, and Figure 3.13).  MALDI IMS of 
transverse sections through the kidney showed that these signals were present in the 
cortex of the kidney.  Treatment of diabetic mice with PM, did not significantly affect 
Amadori-PE levels (Figure 3.12 and Table 3.2), however, a tendency toward lower 
levels was observed in renal specimens from PM-treated mice (Table 3.2).  Again, 
examining different time points and mouse models, the levels of Amadori-PEs seemed 
to correlate with the degree of renal pathology (Figure 3.13). 
To determine more precise localization patterns of Amadori-PE species within 
the renal cortex, a region of the cortex in the diabetic kidney was imaged at high spatial 
resolution with a 10 µm step size (Figure 3.14).  First, we found that PE lipids were not 
uniformly distributed throughout the cortex but had uniquely localized patterns.  Further, 
we established that the unmodified and the Amadori forms of the same lipid species co-
localize to the same areas of the cortex.  This can be seen in Figure 3.14A where PE (P-
18:0/20:4) and Amadori-PE (P-18:0/20:4) show the same localization pattern.  
Additionally, we determined that the majority of Amadori-PE species follow two major 
localization patterns in the renal cortex exemplified by the complementary patterns of
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Figure 3.12. Analysis of glucose-modified (Amadori) phosphatidylethanolamine (PEs) 
species in non-diabetic, diabetic, and diabetic + PM mouse kidneys.  (A) FTICR IMS at 
40 µm of transverse kidney sections showing localization and relative abundance of two 
different PE lipids along with their corresponding Amadori species. These glucose-
modified species were detected in the cortex of the diabetic kidneys but not in non-
diabetic kidneys. The colors represent relative signal intensity according to the scale bar 
on the right. (B) Identification of lipid species using Amadori-PE (16:0/20:4) as an 
example.  The FTICR MS/MS spectrum with Amadori-PE (16:0/20:4) molecular ion (m/z 
900.56), product ions and product ion assignments (inset) are shown.   
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 Ratio of Amadori-PE  to PE, % 
Treatment PE (16:0/20:4) PE (16:0/22:6) PE (P-18:0/20:4) PE (P-18:0/22:6) 
Control 0.4 ± 0.4 0.3 ± 0.3 0.2 ± 0.1 0.3 ± 0.2 
Diabetic 23.2 ± 9.4* 18.9 ± 6.8* 17.5 ± 8.9* 16.1 ± 5.7* 
Diabetic + PM 8.5 ± 2.5 7.4 ± 2.5 6.1 ± 1.8 7.8 ± 2.3 
 
 
 
Table 3.2. Relative quantitation of Amadori-PE levels within renal cortex. Ratio of 
integrated Amadori-PE signal to unmodified PE signal from kidney imaging experiments. 
* - p <0.05, diabetic vs. non-diabetic groups.  
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Figure 3.13. Analysis of glucose-modified (Amadori) phosphatidylethanolamine (PE) 
species in kidneys of different mouse models. Glucose-modified PE was determined in 
13 and 22 week old eNOS
-/-
 db/db mice (A), and in 22 week old db/db and eNOS
-/-
 mice 
(B). Imaging was performed using FTICR MS at 40 µm spatial resolution in the cortex 
region of the kidney. 
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Figure 3.14. High spatial resolution (10 µm) MALDI FTICR IMS of glycated 
phosphatidylethanolamines (PEs). (A) Unmodified PEs and corresponding Amadori-PEs 
are co-localized to the same areas of the cortex. As an example, an overlay of PE (P-
18:0/20:4) (green) and Amadori-PE (P-18:0/20:4) (red) shows co-localization in yellow. 
(B) Two distinct spatial localization patterns of glycated PE species in the renal cortex. 
Amadori-PE (16:0/22:6) (blue) displays the opposite localization pattern to Amadori-PE 
(P-18:0/20:4) (red, shown as a single ion image in panel A).  (C) Zoom in on the IMS 
overlay from panel B (left) and corresponding region of the same section after staining 
with PAS (right). Amadori-PE (P-18:0/20:4) (red) is localized to glomeruli and some 
tubules while Amadori-PE (16:0/22:6) (blue) is localized to a distinct set of tubules. g = 
glomerulus  
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Amadori-PE (16:0/22:6) and plasmalogen Amadori-PE (P-18:0/20:4) (Figure 3.14B). 
The former is localized exclusively to a distinct set of tubules while the latter has a 
mixed glomerular and tubular localization (Figure 3.14C).  
Discussion 
Progress in science and medicine is closely associated with development of new 
experimental technologies that allow investigations to answer previously intractable 
questions concerning biological differences in normal and diseased tissue.  The recent 
development of MALDI IMS technology enables molecular profiling of specific areas of 
the tissues while preserving tissue morphology.  As demonstrated in this study, it is now 
possible to analyze the molecular composition and molecular modifications in distinct 
renal tissue regions and even within smaller structures, such as glomeruli and tubules.  
With the expected further improvement of spatial resolution (<1 µm), specific structural 
features within the glomerulus such as mesangium, GBM and even individual 
glomerular cells could be targeted for analysis.   
Here, we utilized MALDI IMS technology to determine DN-related changes of 
molecular species from four major lipid classes in renal cortex, including individual 
glomeruli and tubules, determined directly from thin kidney sections.  We employed a 
mouse model of DN known to exhibit severe renal damage
125
 which was also observed in 
our study (Figure 3.1 and 3.2).  Additionally, PM treatment was utilized in one 
experimental group which showed a reduction in albuminuria (Figure 3.1).  This is 
consistent with the observed protective effects of PM on renal function demonstrated in 
several diabetic animal models
24, 26, 28, 126
 and in clinical trials, particularly at the early 
stages of the disease.
25, 127
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Previous studies reported changes in ganglioside levels and metabolism in 
diabetic animal models.
128-130
  However, this is the first report on specific glomerular 
localization and levels of major gangliosides in DN.  Of particular interest is the observed 
dramatic increase in the levels of NeuGc-GM3 in diabetic glomeruli (Figure 3.3).  As 
sialic acids are synthesized via a branch of the glycolytic pathway, the increased flux 
through this pathway in diabetes may contribute to such increase.  However, since sialic 
acid NeuAc is a precursor of NeuGc and ganglioside NeuAc-GM3 did not increase in 
diabetes (Figure 3.3A, top row) this mechanism is unlikely.  Alternatively, NeuGc-GM3 
may derive via non-enzymatic hydroxylation of the acetyl moiety of NeuAc-GM3 by 
hydroxyl radicals produced in diabetic oxidative stress.
131, 132
  This mechanism is 
consistent with decreased NeuGc-GM3 levels in the glomeruli of diabetic mice treated 
with PM, which has been shown to scavenge hydroxyl radical under high glucose 
conditions.
20, 21
  Interestingly, unlike in all other mammals, ganglioside NeuGc-GM3 is 
not metabolically produced in humans and is present only at trace levels in normal human 
tissues, most likely due to dietary sources.
133
  However, NeuGc-GM3 is significantly 
increased in many human tumors where it may act as xeno-autoantigen causing chronic 
inflammation.
133
  Therefore, it is possible that diabetic oxidative stress facilitates 
oxidation of NeuAc-GM3 and accumulation of NeuGc-GM3 in glomeruli, thus 
contributing to chronic inflammation in DN.  
 Our results suggest that sulfoglycolipids may play a role in DN pathogenesis. The 
exact mechanism remains to be elucidated.  However, it is interesting that isolated rat 
renal tubules exposed to exogenous glucose in vitro showed increases in the levels of 
SM2a and SB1a but not SM3 sulfoglycolipids,
134
 similar to our results in DN mouse 
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model (Figure 3.6).  Experiments using cerebroside sulfotransferase (CST) knock-out 
mice, which do not synthesize sulfoglycolipids, have demonstrated significant reduction 
in monocyte infiltration of renal interstitium after ureteral obstruction in the knock-out 
compared to the wild-type mice.  These studies suggested that sulfoglycolipids may 
promote renal inflammation and tubulointerstitial injury, possibly via ligation of L-
selectin.
135
 
  It is well established that lysophospholipids (LPLs) are important signaling and 
regulatory molecules involved in multiple pathogenic pathways.
119, 120
  LPL species may 
regulate cell signaling through altering the structure and fluidity of a lipid bilayer, 
particularly above their critical micelle concentration (CMC).
120
  In this regard, the 
significant increase in glomerular LPL demonstrated in our study may facilitate CMC 
transition, thus affecting activities of membrane proteins.
136, 137
   However, most of the 
biological effects of LPL are mediated via G-protein coupled receptors.  Particularly 
interesting is pro-fibrotic activity of lysophosphatidic acid (LPA) mediated via LPA1 
receptor as has been demonstrated in UUO mouse model of renal fibrosis.
138
  More 
recently, the receptor for advanced glycation end products (RAGE) has been shown to 
mediate pro-inflammatory action of LPA.
139
  Since expression of RAGE is upregulated in 
diabetic kidney,
140
 LPA-RAGE interaction may contribute to inflammatory damage in 
DN.  Involvement of lysophosphatidylcholine (LPC) in renal pathology is indirectly 
suggested by the elevated LPC levels in plasma of patients with renal disease.
141, 142
  In 
the in vitro studies, LPC induced proliferation of cultured mesangial cells via a 
mechanism involving activation of EGF receptor signaling.
143
  LPC is also a ligand for 
two G-protein coupled receptors G2A and GPR4, which are expressed in many human 
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tissues including kidney.
144, 145
  It is yet unknown whether these receptors are involved in 
pathogenesis of renal disease.   
 While prior studies have shown the elevated levels of Amadori-PEs in plasma of 
diabetic patients and in different organs of diabetic animal models,
121, 122
 ours is the first 
report establishing a relationship between glycated PEs and DN.  Glycated PEs have been 
shown to alter the structure and stability of cell membrane proteins and promote lipid 
peroxidation,
123, 146
 thus exhibiting pathogenic potential.  Our results suggest that 
Amadori-PEs play a minor role in DN pathogenesis. The levels of different Amadori-PE 
species in renal cortex were significantly elevated in diabetes but were not significantly 
inhibited upon PM treatment, even though a tendency toward lower levels was observed 
(Table 3.2).  The notion that non-oxidative glucose adduction to PE has low 
pathogenicity is consistent with the previous findings using mice deficient in 
fructosamine-3-kinase (FN3K), the enzyme that facilitates dissociation of Amadori 
adducts to amino groups. These mice did not exhibit a pathogenic phenotype in any 
organs, including kidney, despite having significantly elevated levels of Amadori-
modified tissue proteins.
147
  
 In summary, our data demonstrate that the levels of specific phospho- and 
glycolipids in glomeruli and/or tubules of the kidney are associated with diabetic renal 
pathology.  These lipid changes were detected in tubules and glomeruli, major sites of 
DN lesions and corresponded with the level of renal damage in the time course studies as 
well as in the models with different extent of renal damage.  Through the use of PM, we 
also demonstrated that the inhibition of non-enzymatic oxidative pathways ameliorated 
lipid levels and renal pathology, suggesting that hyperglycemia-induced oxidative 
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pathways are required for the observed changes of lipid profiles in DN.  The propensity 
to these oxidative pathways may contribute to individual susceptibility to DN in diabetes. 
Methods 
Animal studies. Animal experiments were performed at the AAALAC-accredited 
animal facilities at Vanderbilt University Medical Center according to institutional 
guidelines and IACUC-approved experimental protocol.  Mice were housed in a 
pathogen-free barrier facility and given standard chow (Lab Diet 5015; PMI Nutrition 
International, Richmond, IN) and water ad libitum.  Upon development of hyperglycemia 
(about 6 wks of age), eNOS
-/-
 C57BLKS db/db mice were randomized according to body 
weight and assigned to either diabetic or diabetic/PM treatment groups.  Mice in 
diabetic/PM treatment group received PM in drinking water at a daily dose of 400 mg/kg 
body weight, based on previously published reports of PM protection from kidney injury 
in diabetic mice.
26
  To minimize possible chemical degradation of PM, a light-sensitive 
compound, fresh solutions were prepared twice a week and administered in water bottles 
wrapped in aluminum foil as previously described.
148
 PM treatment continued until mice 
were sacrificed at 22 wks of age.  The control group included wild type C57BLKS mice. 
Kidneys were removed and either fixed for histological analyses by light and electron 
microscopy or flash frozen in liquid nitrogen and stored at -80°C for IMS analyses.  
Determination of blood glucose and urinary albumin excretion. Glucose levels 
were measured in blood collected from the tail vein using OneTouch glucometer and 
Ultra test strips (LifeScan, Milpitas, CA) as previously described.
106, 149
  Albumin and 
creatinine excretion was determined in spot urine collected from individually caged mice 
using Albuwell-M kits (Exocell Inc, Philadelphia, PA) as previously described.
106, 149
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Histological Analyses. Renal histology was assessed in mice at 22 weeks of age. 
The kidneys were removed and fixed overnight in 10% formalin at 4°C, and 3-μm-thick 
sections were stained with periodic acid-Schiff (PAS) and Jones’ silver staining.  
Histological evaluation by light microscopy was performed without knowledge of the 
identity of the various groups. A semi-quantitative index was used to evaluate the degree 
of glomerular mesangial expansion and sclerosis. Each glomerulus on a single section 
was graded from 0 to 3, where 0 represents no lesion, and 1, 2, and 3 represent mesangial 
matrix expansion or sclerosis, involving < 25, 25 to 50, and > 50% of the glomerular tuft 
area, respectively. 
 For electron microscopy, kidneys were cut into small tissue blocks (1 mm
3
) and 
fixed in 2.5% glutaraldehyde fixative with 0.1 mol/L cacodylate buffer, pH 7.4, overnight 
at 4°C. After postfixation with 1% osmium tetroxide, tissues were dehydrated in a series 
of graded ethanol preparations and embedded in epoxy resin (Poly/Bed 812 Embedding 
Media; Polysciences, Warrington, PA). Ultrathin sections were stained with uranyl 
acetate and lead citrate. Sections were observed by transmission electron microscopy (H-
7000; Hitachi, Tokyo, Japan) at 75 kV to determine TBM and GBM thickness. 
MALDI mass spectrometry. MALDI TOF Lipid Imaging: Frozen kidneys were 
sectioned on a cryostat at 8 µm thickness, thaw mounted on conductive indium tin oxide 
coated glass slides, and dried in a desiccator.  The tissue sections were washed by dipping 
the slide in 50 mM ammonium formate at 4°C three times for five seconds each to 
remove salts and increase the sensitivity for lipid analysis.
76
  MALDI matrix was applied 
using a custom built sublimation apparatus which uses reduced pressure and heat for 
vapor deposition of the MALDI matrix on to the sample slide
61
 resulting in a uniform 
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MALDI matrix coating over the tissue.  1,5-Diaminonaphthalene (DAN) was sublimed at 
110°C and 50 mTorr for 7 minutes.  The resulting matrix coating contained 0.13 ± 0.02 
mg DAN/cm
2
.  MALDI imaging experiments were performed in negative ion mode using 
a Bruker Ultraflextreme time-of-flight (TOF) mass spectrometer in reflectron geometry.  
Spectra were collected in the range of m/z 400-1500 with 10 shots/spectra.  Raster steps 
were taken in 10 µm stage increments and the laser spot size was also 10 µm in diameter 
as measured on a thin matrix coating.  Each imaging experiment was run as a set 
containing a kidney section from each experimental group.  Areas of the cortex were 
selected for imaging of approximately 20,000 pixels per kidney.  FlexImaging was used 
for image visualization.   
MALDI FTICR Lipid Imaging: Frozen kidneys were sectioned as above.              
9-aminoacridine (9-AA) MALDI matrix was applied by sublimation at 140°C and 50 
mTorr for 12 minutes.  The resulting matrix coating contained 1.1 ± 0.2 mg 9-AA/cm
2
.  
MALDI imaging experiments were performed in negative ion mode using a 9.4 T 
SolariX MALDI Fourier transform ion cyclotron resonance (FTICR) mass spectrometer 
(Bruker Daltonics).  Spectra were collected in the range of m/z of 400-1500 with 500 
shots/spectra. Image resolution was set at 40 µm or 10 µm.  FlexImaging and 
DataAnalysis were used for image visualization and data analysis.   
After all imaging experiments, the MALDI matrix was removed from the slides 
by immersion in 70% ethanol followed by 95% ethanol for 30 s each.  Kidney sections 
were then stained with PAS and renal tissue structures were matched to MALDI IMS 
data via image overlay. 
84 
 
Lipid Identification: All lipids reported were identified using MS/MS 
fragmentation along with accurate mass data.  Accurate masses were determined after 
imaging experiments by profiling an adjacent tissue section using MALDI FTICR MS.  
Phospholipid species were isolated and fragmented with the FTICR MS using sustained 
off-resonance irradiation collision-induced dissociation (SORI-CID) for identification.  
Glycolipid species MS/MS fragmentation experiments were performed on a MALDI-
LTQ-XL hybrid linear ion trap instrument (Thermo Scientific) using pulsed q-
dissociation.  The LipidMaps database (lipidmaps.org) was used to search the accurate 
mass data.  Fragmentation patterns were interpreted manually along with tools from 
lipidmaps.org.   
Relative quantitation of lipid levels. For the MALDI imaging datasets, ImageJ 
software (National Institutes of Health, Bethesda, MD, USA) was used to measure the 
relative abundance of the lipid species of interest between experimental groups.  
Monochromatic TIFF images were exported from FlexImaging to ImageJ.  Areas of 
interest were selected in each image as individual glomeruli, tubules, or the entire kidney 
section.  Signal intensity was measured as the mean intensity per area of interest (i.e.- 
glomeruli, tubules, or entire kidney cross-section).  Glomerular and tubular signals were 
evaluated as single ions and the Amadori-PEs were evaluated as the ratio of the Amadori-
PE signal to the unmodified PE signal. 
Statistical analysis. Data were expressed as means  SEM and statistical analysis 
was performed using Student’s t test for unpaired samples or ANOVA followed by post-
hoc Student-Newman-Keuls comparisons.  For the MALDI imaging datasets, the mean 
and standard error were calculated for each MS peak of interest.  Differences were 
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evaluated by the Kruskal-Wallis rank-sum test followed by post-hoc Tukey test.  
Differences were considered statistically significant if p values were less than 0.05. 
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CHAPTER IV 
 
HIGH SPATIAL RESOLUTION IMAGING MASS SPECTROMETRY FOR 
DETECTING SPATIAL DISTRIBUTIONS OF PROTEINS IN HEALTHY, 
DIABETIC AND DIABETIC TREATED KIDNEYS 
 
Overview 
  Imaging mass-spectrometry (IMS) allows for molecular profiling of specific 
morphologically distinct tissue regions, such as fibrotic glomerular lesions, without 
disturbing the overall tissue morphology. For this study, a robust mouse model of 
diabetes (eNOS
-/-
 db/db) with and without pyridoxamine (PM) treatment was investigated 
with high spatial resolution IMS to investigate protein expression changes in 
microstructures of kidney sections. We report histology-directed analysis of individual 
glomeruli as well as 25 µm MALDI IMS which revealed molecular localization at the 
level of single glomeruli and tubules. Differential relative abundances of a number of 
protein signals were found between the experimental groups. Identified markers with 
increased expression in DN included fibronectin, fragments of albumin and fragments 
alpha-1-antitrypsin (A1AT). These proteins were found to be absent or attenuated in the 
non-diabetic and PM treatment groups.  
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Introduction 
 While diabetic nephropathy (DN) takes years to develop, it is largely irreversible 
and remains a major health complication for diabetic patients. The pathogenic 
mechanisms underlying this disease remain unclear and so uncovering molecular events 
that define mechanisms of susceptibility and disease progression can improve early 
detection and provide potential targets for drug therapy. Proteomic technologies have 
been used in this vein to discover biomarkers and uncover proteins and pathways that 
contribute to the pathophysiology of the kidney. A number of previous proteomic studies 
have looked for biomarkers in the urine and blood
151-154
 but fewer have looked in the 
kidney itself.
35, 89, 155, 156
 The ability to localize molecular changes in tissue, at the site of 
disease, may provide insight into new molecular markers and provide a better 
understanding of disease progression. 
Here, on-tissue histology-directed profiling and high spatial resolution imaging 
has been used to determine protein changes in the kidney of a robust model of DN, the 
eNOS-/- db/db mouse. The present study is the first report of direct kidney MALDI IMS 
for protein analysis with the spatial specificity to analyze individual renal glomeruli and 
tubules. Proteomic signatures that correlated with disease were identified and their 
localization within the kidney was determined. The relative abundance of these signatures 
was evaluated after treatment with PM; an experimental drug being that has been shown 
to slow the progression of kidney disease.
25, 28, 127
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Results 
Histology-directed profiling for protein expression in glomerular lesions. 
Histology-directed MALDI IMS was utilized to analyze individual glomeruli in renal 
sections of wild-type mice and eNOS
-/-
 db/db mice which develop robust DN.
106
 
Glomeruli from eNOS
-/-
 db/db mice exhibited significant ECM deposition in PAS-stained 
sections (Figure 4.1A). Kidney sections were stained with cresyl violet, a stain that does 
not interfere with MALDI MS, and glomeruli were identified and selected for trypsin 
spotting (Figure 4.1B). After in situ tissue digestion, tryptic peptides from the individual 
glomeruli were analyzed by MALDI MS and the most abundant peptide signals were 
identified using tandem MS. In the MS spectrum from a single diabetic mouse 
glomerulus (Figure 4.1C), a peptide at m/z 1906 was identified as a tryptic fragment of 
fibronectin (Figure 4.1D). The fibronectin deposition was detected in glomeruli but not in 
non-glomerular cortical areas of the diabetic mice. In the wild-type mice, levels of 
fibronectin were not statistically different from the background noise (Figure 4.1E). The 
peaks at m/z 1363 and 2572 were also identified as fibronectin peptides and exhibited 
similar intensity patterns as the fibronectin tryptic peptide at m/z 1906. In addition, peaks 
at m/z 1529 and 1274 were identified as tryptic fragments of hemoglobin, a peak at m/z 
1744 was a tryptic fragment of histone H2B, and the peak at m/z 1198 was a tryptic 
fragment of smooth muscle actin (Figure 4.1C).  
Proteomic studies have established that protein abundance in complex biological 
samples is proportional to the abundance of corresponding proteolytic peptide 
fragments.
157, 158
 In MALDI IMS studies, the intensities of proteolytic peptide ions 
resulting from in situ trypsin digestion corresponded to the intact protein ion intensity.
96
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Figure 4.1. Identification of fibronectin deposition in individual glomeruli. (A) PAS 
stained glomerulus from eNOS
-/-
 db/db kidney section exhibiting abnormal extracellular 
matrix deposition and sclerotic regions. (B) Cresyl violet stain of the same glomerulus 
shown in panel A from a serial kidney section. (C) MALDI MS spectrum of tryptic 
peptides from a selected glomerulus; peptide at m/z 1906 was sequenced using tandem 
MS mode. (D) Tandem MS (MS/MS) spectrum and corresponding amino acid sequence 
of the peptide at m/z 1906; the peptide was identified as a tryptic fragment of fibronectin 
by searching mouse SwissProt database with MASCOT software. (E) MALDI MS 
spectra in the region of the tryptic fibronectin peptide at m/z 1906 from glomeruli and 
non-glomerular cortex areas of eNOS
-/-
 db/db and wild-type mice. Increases in renal 
fibronectin deposition occurred specifically in glomeruli of eNOS
-/-
 db/db mice. 
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Therefore, we used the abundance of fibronectin peptide with m/z 1906 to determine 
relative deposition of fibronectin in different areas of the kidney and in kidney glomeruli. 
Ten random glomeruli from each kidney section of wild-type mice, eNOS-/- db/db mice 
and PM treated eNOS-/- db/db mice were subjected to in situ tryptic digestion followed 
by MALDI MS analysis. As shown in Figure 4.2A and B, glomerular fibronectin 
deposition was significantly increased in eNOS
-/-
 db/db mice and PM treatment reduced 
the amount of glomerular fibronectin deposition in eNOS
-/-
 db/db mice. This increase in 
fibronectin deposition by IMS was consistent with that determined using classical 
immunohistochemistry (Figure 4.3). Interestingly, there was also ~2.5-fold increase in 
smooth muscle actin, a well-known marker of DN,
159
 in the eNOS
-/-
 db/db glomeruli 
compared to that of control. This increase was completely inhibited in PM treated   
eNOS
-/-
 db/db mice.  
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Figure 4.2. Treatment of eNOS
-/-
 db/db mice with PM inhibited glomerular fibronectin 
deposition. (A) MALDI MS spectra of tryptic fibronectin peptide at m/z 1906 were 
determined in glomeruli of non-diabetic wild type C57BKS mice (dotted line), eNOS
-/-
 
db/db mice (dashed-and-dotted line), and eNOS
-/-
 db/db mice treated with PM (solid 
line). (B) The mean intensity of tryptic fibronectin peptide at m/z 1906.  * - the difference 
between eNOS
-/-
 db/db and WT was significant,  P < 0.001 (n=10);  ** -  the difference 
between eNOS
-/-
 db/db and eNOS
-/-
 db/db  + PM was significant,  P < 0.001 (n=10).  
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Figure 4.3. Increase in glomerular fibronectin deposition in eNOS
-/-
 db/db mice by 
MALDI MS and validation by IHC. MALDI MS spectra in the region of the tryptic 
fibronectin peptide at m/z 1906 from glomeruli of wild type (A) and eNOS
-/-
 db/db (B) 
mice. Immunohistochemical analysis of fibronectin deposition in wild type (C) and 
eNOS
-/-
 db/db (D) mice using fibronectin antibody.  
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High spatial resolution MALDI IMS reveals protein differences in specific 
regions of DN kidney cortex. Protocols were developed for high spatial resolution 
MALDI IMS protein analysis of small renal structures such as glomeruli and tubules. 
Kidney sections were coated with CHCA matrix by sublimation which produced a 
uniform coating with crystal sizes ~1 µm. After sublimation and deposition of the matrix 
on to the tissue surface, the slides were rehydrated in a humid environment which 
increased protein incorporation into the matrix layer. High spatial resolution imaging was 
performed on thin kidney sections from DN and wild type mice to determine protein 
expression differences between the experimental groups. Tissues were imaged at a 25 µm 
spatial resolution in the mass range of m/z 1000 to 25000 and then co-registered with the 
PAS stained histology image of the same section. At this spatial resolution, and with co-
registration, features such as glomeruli could be determined in the MALDI IMS data. 
 Since the glomerulus is one of the structures known to be damaged in DN, we 
examined the protein expression differences in the glomeruli between the experimental 
groups. Figure 4.4 shows the average spectra from glomeruli of non-diabetic and DN 
kidneys. Signals such as m/z 1851, 4343, 4965, and 15600 were present in all glomeruli. 
Several signals were found to be increased in DN glomeruli such as m/z 3650, 4415, and 
8710. The signal at m/z 4415 was particularly interesting because it has a mass difference 
of 72 Da from the common glomerulus signal at m/z 4343. Because a mass shift of 72 Da 
could represent a carboxyethyl lysine (CEL) modification, a known AGE to be increased 
in DN, the expression and localization of this signal was examined more closely. 
Additionally, we were interested in the expression of this signal in the PM treated mouse 
kidney, since PM is an inhibitor of AGEs. Figure 4.5A shows the localization of m/z 4343 
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Figure 4.4. Average spectra from glomeruli in non-diabetic and diabetic mouse kidneys. 
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Figure 4.5. High spatial resolution IMS shows protein changes in glomeruli of diabetic 
kidneys. (A) MALDI IMS of kidneys imaged at 25 µm spatial resolution showed a signal 
at m/z 4343 localize to glomeruli of all experimental groups.  A signal at m/z 4415 (+72 
Da from m/z 4343), localizes specifically to the diabetic glomeruli and is absent in the 
non-diabetic glomeruli. (B) The signal at m/z 4415 is present in glomeruli with more 
intense PAS staining.   
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and m/z 4415 in kidneys of each experimental group. The signal at m/z 4415 was not 
present in the glomeruli of wild type kidneys. In the PM treated animals, this signal was 
lower than in the untreated counterparts. Because this signal was not completely absent in 
PM treated glomeruli, we wanted to more closely examine the glomeruli where this 
signal was localized. As seen in Figure 4.5B, this signal in present in more sclerotic 
glomeruli as determined by the more intense pink staining from the PAS which highlights 
extracellular matrix.  
Beyond the differences in the glomerulus, the high spatial resolution imaging 
revealed a number of other signals to be differential between the wild type and DN 
kidneys. These signals were present in discrete regions in the DN kidney and one 
example is shown in Figure 4.6. It was not obvious based on histology or mass spectral 
patterns what the corresponding region in the wild type kidney was to compare it with. 
Because of this, spectra from across the tissue were extracted for further analysis. About 
1,000 spectra from each a wild type cortex and a DN cortex were loaded into 
ClinProTools (Bruker) for peak picking. The integrated areas of 240 peaks were 
calculated for all individual spectra. The free statistics program Tanagra was used for 
further analysis of this set of peaks.  PCA was performed and a plot of the first two 
principle components is shown in Figure 4.7A. The first principal component was able 
to describe the variation between the wild type spectra and the DN spectra in this 
dataset. Therefore, the loadings of the first component were examined to determine what 
peaks influenced this separation (Figure 4.7B). These peaks were examined in the 
imaging datasets of biological replicates and peaks which showed a consistent pattern 
were selected for further analysis.  
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Figure 4.6 Low molecular weight species increased in diabetic kidney cortex. An 
example of one low molecular weight species, m/z 1903, that was not detected in the non-
diabetic kidney and present in the diabetic kidney with a highly localized distribution. 
The top right shows the average spectrum from the non-diabetic kidney. The bottom 
spectrum shows the average selected spectrum from the region of interest shown to the 
left. There is an increase of signals in the range of 1-4.5 kDa. Imaging performed with 
MALDI IMS at 25 µm. 
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Figure 4.7. PCA based differentiation of spectra from IMS. (A) Scores plot of the first 
two principle components differentiating spectra from IMS of diabetic (red circles) and 
non-diabetic (green triangles) kidneys. (B) Plot of loadings from PC1 vs each m/z. 
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Identification of peaks from IMS. A number of peaks could differentiate wild 
type and DN kidneys; however, it is important to determine the molecular identity to 
investigate the biological roles. Because many of the peaks of interest were localized to 
small regions of the tissue, targeted approaches were necessary for identification. Two 
strategies were used to identify peaks of interest from the IMS experiments: image 
directed on-tissue MS/MS of peaks 1-3kDa and LC-MS/MS of homogenized serial 
sections targeting IMS signals of interest using top-down electron transfer dissociation 
(ETD) for fragmentation. Additionally, high mass resolution on-tissue MS was performed 
using a 15T FTICR MS on diabetic kidneys for accurate mass measurements to assist in 
identification. Table 4.1 lists proteins identified. Of particular interest were signals 
related to albumin and alpha-1-antitrypsin (A1AT) and these were further investigated.  
Identification and localization of alpha-1-antitrypsin. Closer examination of the 
discriminating peaks revealed two unique sets of peaks increased in diabetic kidneys 
(Figure 4.8A). The three signals in each peak set showed the same localization and were 
each separated by 14 Da. The first peak in both sets was targeted for ETD MS/MS 
(Figure 4.8B) by selecting precursor ions at m/z 589.5, [M+7H
+
]
7+
 and m/z 601.9, 
[M+7H
+
]
7+
 which correspond to the MALDI TOF peaks at m/z 4120 and m/z 4208, 
respectively. These two peaks were identified as C-terminal fragments of alpha-1-
antitrypsin 1-4, differing by one serine amino acid. In the mouse, alpha-1-antitrypsin 
(A1AT) is represented by a cluster of related genes. Based on accurate mass 
measurements the sets of triplicate peaks which are separated by 14 Da are most likely 
the same C-terminal 35 and 36 fragments of alpha-1-antitrypsin 1-2 and alpha-1- 
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Table 4.1. Table of identified proteins. Italicized entries are probable identifications based on 
FTICR MS measurements. The parentheses annotate the amino acid sequence and modifications 
represented by the signal.  
MALDI 
TOF m/z 
Clusters 
With 
Identification ID Method 
1018 DB Albumin (359-366) LIFT 
1108 DB Albumin (356-363) LIFT 
1211 DB Napsin-A (387-398) LIFT 
1237 DB Albumin (557-567) LIFT 
1474 DB Albumin (356-366) LIFT 
1479 DB Albumin (557-569) LIFT 
1802 DB Histone H2A (115-130) LIFT 
2008 DB Transgelin (183-201) LIFT 
2042 DB Albumin (557-574) LIFT 
2398 DB Transgelin (179-201) LIFT 
2665 DB Albumin (26-48) LIFT 
2794 DB Albumin (25-48) LIFT 
4120 DB A1AT (379-413) ETD 
4208 DB A1AT (378-413) ETD 
4938 DB Thymosin B10 (2-44 acetylated) ETD 
4965 DB Thymosin B4 (8-50 acetylated) ETD 
5445 WT 
Cytochrome C oxidase polypeptide 7C 
(17-63) 
Accurate Mass 
5708 WT 
ATP synthase subunit epsilon, 
mitochondrial (2-52) 
Accurate Mass 
8709 DB Apolipoprotein A-II (25-102) 
Trypsin Bottom  
up, LIFT 
8944 WT 
ATP synthase-coupling factor 6, 
mitochondrial (33-108) 
ETD 
9912 WT 
Acyl-CoA-binding protein (2-87 
acetylated) 
ETD 
9978 WT 
Cytochrome c oxidase subunit 6B1 (2-
86, acetylated, 2 disulfide bonds) 
ETD 
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Figure 4.8. MALDI and ESI analysis of C-terminal fragments of A1AT. (A) MALDI FTICR 
spectrum from diabetic kidney tissue showing C-terminal A1AT fragments present in the 
diabetic mouse kidney. The first set of peaks represents the C-terminal 35 amino acids of three 
forms of A1AT while the second set of peaks represents the C-terminal 36 amino acids. (B) ETD 
fragmentation spectrum of m/z 589.5, [M+7H
+
]
7+
 (inset, corresponds with m/z 4120.17 [M+ H
+
]
+
 
from panel A) which was identified as the C-terminal 35 amino acids of A1AT 1-4.  
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antitrypsin 1-1. A1AT 1-2 differs from A1AT 1-4 by one leucine in place of one valine amino 
acid while A1AT 1-1 has two leucines in place of two valines from A1AT 1-4. These amino acid 
differences would result in mass shifts of 14 Da each. Figure 4.9 shows the spatial distribution of 
the C-terminal 35 amino acids at m/z 4120 along with the relative abundance of this signal in the 
kidney determined from three biological replicates in each group. Both the images and relative 
quantitation show a clear increase in this signal in the diabetic kidney and a decrease with PM 
treatment. Additionally, this signal appears to be more concentrated in cast regions of the 
diabetic cortex.  
Albumin fragments in the DN kidney. On tissue MS/MS analysis revealed a number of 
albumin fragments were present in diabetic kidneys (Table 4.1). To further investigate this, high 
mass resolution IMS was performed on diabetic kidneys using a 15T FTICR MS. Mass signals 
were then compared to theoretical albumin fragments using the FindPept tool from ExPASy 
(http://web.expasy.org/findpept). This search returned a number of ‘hits’ that included those that 
already had MS/MS confirmation and additional probable albumin fragments. Interestingly, all 
of the possible albumin fragments originated from three main regions of the intact albumin. 
Table 4.2 lists identified and probable peptides detected in the DN kidneys. Several albumin 
fragments were selected for further analysis to determine the relative abundance of these 
peptides within non-diabetic, diabetic, and PM treated diabetic kidneys. These fragments had 
unique and localized distributions within the diabetic kidney as shown in Figure 4.10. As can be 
seen in the box plots in Figure 4.10, these fragments are dramatically increased in DN and 
further, attenuated by PM treatment.  
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Figure 4.9. Localization and relative abundance of A1AT C-terminal fragment. (A) 
Representative example of m/z 4120 localization in non-diabetic, diabetic, and PM treated 
diabetic kidney cortex. This signal appears to be present in tubular regions of the kidney. (B) 
Relative abundance of m/z 4120 between experimental groups. n = 3 per group. Imaging 
performed with MALDI TOF at 25 µm spatial resolution. 
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Figure 4.10. IMS and relative quantitation of albumin fragments. Imaging performed with 
MALDI TOF at 25 µm spatial resolution. Relative abundance determined by the average 
intensity per imaged region. n=3 per group. 
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Immunofluorescence staining shows tubular localization of albumin fragments. After 
determining the presence of albumin fragments in the DN kidney, we wanted to further 
determine the precise structures where these were localized. Serial sections were cut and MALDI 
IMS was performed on one section at a spatial resolution of 25 µm and immunofluorescence 
staining for tubular specific proteins was performed on the other. Two antibodies were used, one 
which stained proximal tubules, and another which stained distal tubules and collecting ducts. 
The resulting images of the immunofluorescence and IMS were co-registered. Fragments of 
albumin were found in these tubular structures (Figure 4.11). 
Discussion 
DN is characterized by structural and functional changes in glomeruli and tubular regions 
of the kidney cortex; however, much remains unknown about the molecular mechanisms of this 
disease. In this study we sought to detect and identify markers of DN at the site of disease and 
evaluate their response with therapeutic intervention. To do so, histology-directed profiling and 
high spatial resolution imaging was applied to a robust mouse model of DN to determine relative 
protein expression differences in pathologic lesions in microstructures of the kidney.  
Protein mass signals with the specificity to single glomeruli were detected in this study. 
One of these was fibronectin, which through histology-directed profiling we demonstrated 
identification and relative quantitation. Glomerular fibronectin deposition is a prominent known 
feature of diabetic kidney injury.
160
 Previous studies have shown that high glucose can increase 
ECM expression
161, 162
 through reactive oxygen species generation.
163
 In this study, we found 
tryptic peptides of fibronectin increased in glomeruli of eNOS
-/-
 db/db kidneys compared to 
healthy kidney glomeruli.   
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Figure 4.11. Albumin fragments localize in tubules of diabetic kidney. Albumin fragments co-
localize with  dolichos biflorus agglutinin (DBA), a distal tubule and collecting duct marker, and 
Lotus tetragonolobus lectin (LTL), a proximal tubule marker. All scale bars = 200 µm. 
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We also determined that PM treatment attenuated the levels of fibronectin deposition in the 
eNOS
-/-
 db/db kidney glomeruli, suggesting that increased renal ECM deposition involves 
oxidative pathways.  
In addition to profiling, high spatial resolution IMS of intact proteins was used to detect 
expression patterns in glomeruli. Signals at m/z 3650 and 4415 were unique to DN glomeruli and 
may be a marker of disease progression. It was noted that the peak at m/z 4415 in the DN 
glomeruli has a mass shift of +72 Da from a glomerular protein found in the wild type kidney. 
This mass shift is consistent with the AGE modification carboxyethyl lysine and its presence is 
reduced significantly with PM treatment, a known inhibitor of AGE modifications. In the present 
study, identification of this molecule was unsuccessful. Further work is needed to both identify 
this molecule and confirm the modification.  
IMS of the kidney cortex revealed differential signals outside of the glomerulus as well. 
Further, many of these differential signals were identified through targeted approaches. 
Identification of protein peaks from IMS experiments is a challenge and a bottleneck in the IMS 
workflow. Two main approaches commonly used to identify signals from IMS are on-tissue 
fragmentation
164
 and off-line tissue homogenization/extraction and LC separation followed by 
bottom-up or top-down approaches. Efficiency of on-tissue fragmentation can be limited with 
singly charged proteins, particularly for signals >5 kDa, and works best for abundant ions. 
Bottom-up approaches with LC/MS have been used to identify proteins from IMS but it can 
often be difficult to match intact masses from protein databases to those detected in IMS. Top-
down
70, 165, 166
 MS/MS approaches are becoming more popular and useful for identification of 
IMS signals as the intact mass from each experiment can be directly compared. However, 
identification becomes even more of a challenge when signals of interest are localized to very 
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small tissue structures as was the case in this study. Here we used two targeted strategies for 
protein identification that used very little tissue. First, image-directed on-tissue MS/MS was used 
to identify proteins that localized to small tissue structures, where the MS/MS sampling area was 
guided by the IMS data on a serial section. Using this approach a number of albumin fragments 
were identified directly from tissue in highly localized tubule regions. In the second strategy 
several thin serial sections were collected and homogenized followed by a targeted LC-MS/MS 
run. The nearness of the sections to the one imaged helped ensure that the same signals would be 
present in the homogenized sample and targeting the m/z of interest increased the sensitivity of 
analysis versus data dependent approaches.  
A1AT is an inhibitor of serine proteases. It has activity against a number of proteases but 
its main target is elastase, which not only breaks down elastin but other ECM proteins as well. It 
should be noted then that an increase in A1AT could lead to ECM accumulation. Upon 
interaction with a target protease, A1AT is cleaved in its reactive center loop generating a 4kDa 
fragment. Alternatively, non-target proteolytic cleavage has been reported in the reactive center 
loop as well without known inhibitory function.
167-169
 In this study we report two sites in the 
reactive center loop where A1AT is cleaved. Further studies are needed to determine the nature 
and function of these A1AT fragments in the DN kidney. However, in a number of other studies, 
both A1AT and C-terminal fragments of A1AT have been found in the urine of patients with 
diabetes and other forms of kidney damage
151, 152, 170-173
 indicating this protein as a potential 
biomarker of kidney disease.   
It is well established that processing of albumin is mishandled in the diabetic kidney. 
Detection of albumin in the urine indicates kidney damage and is in fact the main diagnostic used 
to assess early disease and disease progression.
3, 174
 It was generally accepted that in healthy 
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kidneys only a small amount of albumin passed through the glomerular filter and then was taken 
up by the proximal tubules and degraded.
175
 The albumin that was not taken up was excreted 
intact in the urine.  While intact albumin is the main measure in the clinic, more studies are 
showing that albumin fragments increase as well and these are not always detected by traditional 
assay methods.
176-178
 The origin of albumin fragments is also of interest. Some studies suggest 
fragments are made in the urine by urine proteases.
173, 179
 While this may happen, others have 
found fragments present in the kidney as well.
180-182
 Our data are in support of the hypothesis 
that albumin fragments are formed in the kidney. We have detected them in post-glomerular 
regions (Figure 4.11) suggesting that they may be formed during processing in the tubules. Our 
data are in agreement with other studies which have suggested that after lysosomal degradation 
in the proximal tubule, albumin fragments are returned to the lumen of the tubule to be excreted 
in urine. The extent of fragments found in our study also seem to correlate with disease severity 
as PM treatment reduced the abundance of albumin fragments detected in the kidney (Figure 
4.10).  
In summary, using IMS, we have demonstrated identification and relative quantitation of 
disease related molecular changes in different renal regions, including individual glomeruli and 
tubules, directly from thin kidney sections. Low molecular weight albumin fragments and C-
terminal A1AT were detected in the DN kidney. Without reducing hyperglycemia, a known 
influencer of kidney damage, PM treatment attenuated these markers of disease. Here, MALDI 
IMS is shown to be a tool to evaluate the efficacy of a therapeutic intervention, identify markers, 
and gain understating of the molecular mechanisms of kidney diseases.  
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Methods 
Mouse model of diabetic nephropathy. Animal experiments were performed at the 
AAALAC-accredited animal facilities at Vanderbilt University Medical Center according to 
institutional guidelines and IACUC-approved experimental protocol.  In this study, we employed 
eNOS
-/-
 C57BLKS db/db mice, the most robust mouse model of Type 2 DN to date.  At >20 
weeks of age, these mice exhibit dramatic albuminuria, arteriolar hyalinosis, increased GBM 
thickness, mesangial expansion, mesangiolysis, focal segmental and early nodular 
glomerulosclerosis, and markedly decreased GFR.
106
  Control group included wild type 
C57BLKS mice.  Experiment continued until mice were sacrificed at 22 wks of age.  Kidneys 
were removed, flash frozen in liquid nitrogen and stored at -80°C. Glucose levels were measured 
in blood collected from the tail vein using OneTouch glucometer and Ultra test strips (LifeScan, 
Milpitas, CA). Albumin and creatinine excretion was determined in spot urine collected from 
individually caged mice using Albuwell-M kits (Exocell Inc, Philadelphia, PA). 
Immunohistochemistry and immunostaining. Immunohistochemical detection of 
fibronectin was performed using an anti-fibronectin antibody (Sigma, St. Louis, MO). The 
kidney sections then were incubated using the avidin-biotin-horseradish peroxidase technique 
(Elite Vectastain ABC kit; Vector Laboratories, Burlingame, CA), and staining was visualized 
using 3,3`-diaminobenzidine. Fluorescein-labeled lotus tetragonolobus lectin (LTL) and 
fluorescein-labeled dolichos biflorus agglutinin (DBA) kits were from VectorLabs (Burlingame, 
CA). Immunostaining was performed as previously described.
183
 
Renal tissue preparation. Frozen kidneys were sectioned on a cryostat at 10 µm 
thickness and thaw mounted on to ITO coated glass slides. Kidney tissue sections were washed 
by immersion in 70% ethanol for 30s, 100% ethanol for 30s, Carnoy’s fluid for 2 min, 100% 
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ethanol for 30s, water for 15s, and then 95% ethanol for 30s. Slides were then stored in a 
desiccator until further processing on the same day. 
Histology-directed profiling: Histology-directed IMS was performed as described 
previously,
66
 with some modifications. After washing, kidney sections were stained with 0.5% 
cresyl violet for 30s followed by an ethanol rinse. The cresyl violet stain aided in distinguishing 
the glomeruli under a microscope and is compatible with MALDI MS. Sample slides were 
scanned using a Mirax slide scanner from Zeiss. Mirax Viewer, Adobe Photoshop, and ImagePro 
were used to identify and record the coordinates of the glomeruli within the kidney sections on 
the digital images. Coordinates of non-glomerular cortical areas were also recorded. The 
coordinates of the selected areas in the kidney were transferred to the automated acoustic robotic 
spotter (Portrait 630, Labcyte) for deposition of trypsin and the MALDI matrix. Trypsin solution 
(76 ng/µL trypsin in 100 mM ammonium bicarbonate/10% acetonitrile) was spotted on the tissue 
(on the glomeruli and non-glomerular cortex coordinates) in single droplets (~120 pL) for a total 
of 40 iterations allowing each droplet to dry for two minutes before spotting the next droplet. 
Proteolytic digestion was allowed to take place for approximately two hours. Subsequently, 
MALDI matrix (10 mg/mL CHCA in 1:1 v/v mixture of acetonitrile and 0.2% trifluoroacetic 
acid) was robotically spotted on the trypsin digested glomeruli.  
For high spatial resolution IMS: MALDI matrix was applied using a custom built 
sublimation apparatus which uses reduced pressure and heat for vapor deposition of the MALDI 
matrix on to the sample slide
61
 resulting in a uniform MALDI matrix coating over the tissue. α-
Cyano-4-hydroxycinnamic acid (CHCA) was sublimed at 135°C and 50 mTorr for 30 minutes. 
Matrix coated sample slides were then rehydrated in a petri dish containing 1 mL of 5% TFA for 
3.5 min at 85°C. 
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MALDI mass spectrometry. Histology-directed profiling: MALDI MS analyses of tryptic 
peptides were acquired on a Bruker UltrafleXtreme TOF/TOF mass spectrometer in positive ion 
reflectron mode. Analysis was performed with 250 shots/spectra.  Digestion peptide profiles 
from the glomeruli were acquired in the range of m/z 600-3900.  Peaks with significant intensity 
changes between the groups were manually selected for MS/MS fragmentation using the LIFT 
mode. The LIFT device raises the potential energy of the ions to induce fragmentation. MS/MS 
spectra were submitted to the MASCOT (Matrix Science) database search engine to match 
tryptic peptide sequences to their respective intact proteins.  
MALDI TOF IMS: MALDI imaging experiments were performed in positive ion mode 
using a Bruker Ultraflextreme mass spectrometer in linear geometry.  Spectra were collected in 
the range of m/z 1000-20000.  Raster steps were taken in 25 µm stage increments and the laser 
spot size was also 25 µm in diameter as measured on a thin matrix coating.  Each imaging 
experiment was run as a set containing a kidney section from each experimental group and areas 
of the cortex were selected for imaging. FlexImaging was used for image visualization.   
MALDI FTICR MS: MALDI imaging experiments were performed in positive ion mode 
using a 15 T SolariX MALDI Fourier transform ion cyclotron resonance (FTICR) mass 
spectrometer (Bruker Daltonics).  Spectra were collected in the range of m/z of 800-10000. 
Image resolution was set at 60 µm. FlexImaging and DataAnalysis were used for image 
visualization and data analysis.   
After all imaging experiments, the MALDI matrix was removed from the slides by 
immersion in 70% ethanol followed by 95% ethanol for 30 s each.  Kidney sections were then 
stained with PAS and renal tissue structures were matched to MALDI IMS data via image 
overlay. 
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Protein Identification. For identification using image-directed on-tissue MS/MS, serial 
sections were cut and mounted on the MALDI target with the same orientation. One section was 
imaged to determine the localization of signals of interest. The imaged tissue was used as a guide 
for regions to sample on the serial section for MS/MS of the peaks of interest. Peaks were 
isolated and fragmented using LIFT mode on a Bruker Ultraflextreme. MS/MS spectra were 
searched using MASCOT. For identification using LC-MS/MS, five sections immediately 
following the section used for IMS were collected in 30 µl of 50% methanol with 0.1% TFA. 
The sample was vortexed and then sonicated for 5 m. The homogenized sample was diluted 10-
fold with 0.1% formic acid and loaded onto a C8 reverse-phase capillary trap column using a 
helium-pressurized cell. The sample in the trap column was then loaded on to an analytical 
column for LC separation followed by mass analysis on a LTQ Orbitrap Velos (Thermo 
Scientific). The instrument was operated using both data-dependent and targeted scan events. To 
determine the mass for the targeted scan events, accurate mass measurements for the singly 
charged peaks of interest were acquired from tissue with a 15T MALDI FTICR MS. Two charge 
states per peak were then calculated to target for fragmentation in the LTQ Orbitrap Velos. For 
LC-MS/MS analyses, full scan (m/z 400-2000) spectra were acquired followed by electron 
transfer dissociation (ETD) fragmentation.    
Relative abundance of protein signals: For the MALDI imaging datasets, ImageJ 
software (National Institutes of Health, Bethesda, MD, USA) was used to measure the relative 
abundance of the protein signals of interest between experimental groups.  Monochromatic TIFF 
images were exported from FlexImaging to ImageJ. Signal intensity was measured as the mean 
intensity per imaged area. 
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Statistical analysis. Data were expressed as means  SEM and statistical analysis was 
performed using Student’s t test for unpaired samples or ANOVA followed by post-hoc Student-
Newman-Keuls comparisons.  For the MALDI imaging datasets, the mean and standard error 
were calculated for each MS peak of interest.   
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CHAPTER V 
 
CONCLUSION AND PERSPECTIVES 
 
High Spatial Resolution Imaging for Elucidating Markers of Kidney Disease 
This project investigated the molecular changes that take place in the glomerulus and 
kidney cortex to explore the pathogenic mechanisms of this disease by use of MALDI IMS. 
MALDI IMS was utilized in this study to image tissue sections of kidneys both in a healthy state 
and in severe DN to elucidate lipid and protein changes that occur with disease. Additionally, the 
response of these lipids and proteins was investigated after treatment with PM, a promising drug 
candidate for the treatment of diabetic nephropathy.   
The first goal of this research project was to develop MALDI MS methods for direct 
tissue analysis of glomeruli and tubules within a kidney cortex by imaging mass spectrometry 
and histology directed profiling techniques. The small size of the glomerulus (~ 75 um in mice) 
had previously made MALDI IMS of this tissue structure a challenge; however, recent advances 
in imaging resolution and sample preparation have made this accessible. Sublimation as a matrix 
application method has been developed for imaging of both lipids and proteins from thin kidney 
sections. SEM analysis (Figure 2.3) showed that this sample preparation technique resulted in a 
homogenous crystal coating lacking gaps with crystal sizes on the order of 1 µm, thus suitable 
for high spatial resolution imaging. Rehydration of the sublimated matrix coating has been found 
to be critical for detection of proteins from tissue. Routine MALDI MS protein imaging is now 
performed at 25 μm spatial resolution (Figure 2.7) and MALDI MS lipid imaging is performed at 
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10 μm spatial resolution (Figure 2.6). At these resolutions the glomeruli are easily imaged within 
the kidney cortex. This work integrated multiple modalities including high spatial resolution 
imaging, high mass accuracy and resolving power measurements, and standard histology (Figure 
2.11) to increase the information measured from tissue sections. 
After developing methods for micro-structure analysis in kidneys, kidneys from three 
experimental groups were studied: wild type (non-diabetic control), eNOS
-/-
 db/db (diabetic) and 
PM treated eNOS
-/-
 db/db mice. The eNOS
-/-
 db/db mouse was chosen for these studies because 
it is one of the most robust models, mimicking the progressive functional and structural damage 
documented in human diabetic nephropathy.  
In Chapter III, high spatial resolution MALDI IMS (10 µm) revealed unique lipid 
expression in small kidney structures such as the glomeruli and tubules of the cortex. 
Identification and renal localization of over 75 lipids was determined (Table 3.1) with many of 
these differentiating disease. Overall, changes in four lipid classes- gangliosides, 
sulfoglycosphingolipids, lysophospholipids, and phosphatidylethanolamines were determined. 
One example is the ganglioside NeuAc-GM3 (m/z 1151.7) and its hydroxylated derivative 
NeuGc-GM3 (m/z 1167.7). The former was found to localize to the glomeruli of all three kidney 
types whereas the latter was observed only in the DN glomeruli (Figure 3.3). Attenuated levels 
of NeuGc-GM3 were observed in PM treated DN glomeruli. Additionally, high mass accuracy 
measurements using FTICR MS indicate early glycation product modifications (Amadori, 
+162.0528 Da) on specific phosphatidylethanolamine (PE) lipids in the diabetic kidney tissue 
(Figure 5.1). It has been found that the modified PEs localize to the cortex region of the diabetic 
kidneys. Over 15 glucose modified PEs have been detected and imaged. This is the first report of 
the detection along with spatial localization of Amadori-PEs in tissue.   
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Figure 5.1. Glucose modified PE’s are increased in the cortex region of the diabetic kidneys.  
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In Chapter IV, protein expression changes were investigated in the kidney cortex of the 
different experimental groups. Specific to glomeruli, fibronectin (Figure 4.2) and a signal at m/z 
4415 (Figure 4.5) were found to be increased. The signal at m/z 4415 is suspected to be a 
carboxyethyl lysine AGE modification on the signal at m/z 4343 based on the co-localization of 
the two signals, the increase in DN, and the reduction with PM treatment. Interestingly this 
marker seems to correlate with more diseased glomeruli (Figure 5.2). Further, other signals 
increased in the DN kidneys were identified which included C-terminal regions of A1AT (Figure 
4.9) and fragments of albumin (Table 4.2, Figure 4.10).  The renal localization and differential 
relative abundance of these proteins between experimental groups was determined. In all cases, 
these were the most abundant in untreated DN tissue and attenuated in PM treated DN kidneys. 
A1AT may have a role in ECM accumulation and albumin is a known marker to increase in 
diabetic urine and so the increased detection of albumin fragments provides further data on how 
its processing is altered in DN. These data provide new molecular insight on what is happening 
in DN and may prove to be useful markers of disease and progression.    
Future Research Directions 
Investigation of Other Organs Affected by Diabetes 
 Future work will extend this study to other organs affected by diabetes.  It is of interest to 
not only explore other molecules that change in organs such as the liver, brain, heart and eyes, 
but to investigate if the findings in the kidney are unique to this organ or extend to other organs. 
The liver is in fact a major source of A1AT and so tracking the expression and form of this 
protein at different stages of diabetes in the liver could be of interest. Additionally, lipids are a 
part of every organ and so determining the expression and localization of modified lipids in 
different organs affect by diabetes should be done. In fact, work is already being done in livers to 
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Figure 5.2. Markers of diseased glomeruli. The signal at m/z 4415 (plotted in red in the MALDI 
image) was found to localize to more sclerotic glomeruli (as observed with the brighter pink PAS 
staining). Note- yellow indicates co-localization of the red and green signals. Scale bar = 50 μm. 
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look for modified PEs. Figure 5.3 shows two different PE modifications detected in the diabetic 
liver, the Amadori-PE that was described in kidneys in Chapter III, and a carboxymethyl (CM)-
PE that is more abundant in the diabetic liver as well. CM is another AGE modification. 
Increasing Spatial Resolution and Sensitivity 
 MALDI imaging was first introduced almost two decades ago. Since this time, aside from 
the applications it was used for, much of the research surrounding it was focused on 
advancements in spatial resolution and sensitivity. Significant progress has been made and these 
efforts are still ongoing. It is expected that routine imaging will soon be performed at a spatial 
resolution of < 1 µm. The average mammalian cell is ~8 µm and so this will provide structural 
resolution below the single cell level. This will truly put IMS on par with standard optical 
pathology but with multiplexed molecular specific images. The level of detail provided at this 
spatial resolution is highlighted in Figure 5.4 where a human kidney section was imaged 
showing a unique display of specific biomolecules highlighting different tubular structures and a 
single glomerulus. This was imaged with a 2 µm spatial resolution using a custom built 
instrument with transmission geometry laser optics to achieve a highly focused beam. As laser 
spot sizes get smaller and smaller however, the number of molecules ablated is reduced as well. 
Much effort will need to be focused on further improving sample preparation and increasing 
sensitivity.   
Application to Human Studies 
 The present study found a number of lipids and proteins that correlated with disease in a 
robust mouse model of DN. It would be of great interest to extend these studies to human 
diabetes to determine if these molecules are involved in human DN pathogenesis and are 
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Figure 5.3. Modified lipids in diabetic livers. (A) Example of an Amadori-PE shown to increase 
in the diabetic liver. (B) Example of a carboxymethyl-PE (CM-PE) shown to increase in the 
diabetic liver. (C) H&E histology of a liver from each group.
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Figure 5.4. Lipid IMS of human kidney section. On the right is an ion image overlay of four lipid 
species imaged at 2 µm spatial resolution using transmission geometry MALDI IMS. On the left 
is a PAS stain of the section serial to the one imaged with IMS. Scale bar = 100 µm.
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biomarkers of human disease. Kidney biopsy is not currently the standard care for 
diagnosis of DN so tissue sources are not abundant. However there are cases where 
biopsy is performed and this could be valuable tissue to apply the methods described in 
this work. New and specific knowledge gained from these studies may lead to more 
accurate diagnosis and prognosis potentially raising the need to reevaluate the use of 
biopsy. The methods described in this work are directly applicable to human tissue for 
both lipid and protein imaging as demonstrated in Figure 5.4 and Figure 5.5, respectively. 
Conclusions 
In summary, high spatial resolution molecular imaging was used to elucidate 
changes in different classes of biomolecules including proteins and lipids in diseased and 
healthy kidneys. These measurements have shown lipid and protein alterations directly at 
the site of disease (i.e. - glomerular and tubular lesions).  Additionally, PM treatment was 
found to reduce the severity of DN assessed by both pathology analysis and molecular 
analysis as determined by imaging mass spectrometry. Without reducing hyperglycemia, 
PM, an inhibitor of non-enzymatic oxidative pathways, attenuated the levels of lipids and 
proteins found in this study to associate with DN. This suggests that these molecules 
require hyperglycemia-induced oxidative pathways. This high resolution imaging 
technology is a powerful tool to determine the spatial context of molecular changes, 
specifically to detect protein and lipid modifications associated with diabetic nephropathy 
from specific structures within the renal cortex. Determining proteins that undergo 
change in disease conditions and evaluating response to treatment may lead to new 
molecular markers of disease, provide insight into disease pathogenesis, and characterize 
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treatment response. This technology can have an impact not just in diabetic nephropathy, 
but any kidney disease as we are measuring minute changes in intact tissue. 
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Figure 5.5.  Protein IMS of human kidney. On the right is a 20 µm spatial resolution IMS 
ion image overlay displaying m/z 1618 (blue), m/z 1950 (white), m/z 2592 (green), m/z 
8415 (yellow), and m/z 13787 (red). The PAS stain on the left is of the same section. 
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